Pseudoxanthoma Elasticum

?

Discussions and Knowledge Gaps

1

Can a disease-modifying therapy that durably restores the pyrophosphate anti-mineralization brake (e.g., bisphosphonate pyrophosphate analogs, recombinant ENPP1, or ABCC6-directed gene therapy) be established for PXE, given that current care is only symptomatic?

KNOWLEDGE GAP OPEN gap_pxe_disease_modifying_therapy

Attached to

pathophysiology#Plasma Pyrophosphate Deficiency

PXE is mechanistically a PPi-deficiency disorder, yet approved therapies only alleviate symptoms. Etidronate reduced calcification and neovascularization in a randomized trial but missed its primary PET endpoint, and pathway-restoring agents (recombinant ENPP1, gene therapy) remain preclinical, leaving a clear unmet need for a proven disease-modifying treatment.

Show evidence (2 references)

DOI:10.3390/ijms22094555 SUPPORT Human Clinical

"At present, therapies only exist to alleviate symptoms for both PXE and GACI"

Confirms that only symptomatic therapy currently exists, defining the disease-modifying-treatment gap.

PMID:29519353 SUPPORT Human Clinical

"In patients with PXE, etidronate reduced arterial calcification and subretinal neovascularization events but did not lower femoral 18fluoride sodium positron emission tomography activity compared with placebo, without important safety issues."

Etidronate shows partial disease-modifying activity but missed its primary endpoint, illustrating the unresolved therapeutic gap.

⚙

Pathophysiology

5

ABCC6 Transporter Loss of Function

PXE is caused by biallelic loss-of-function variants in ABCC6, an ATP-binding cassette transmembrane transporter expressed mainly in hepatocytes. Loss of functional ABCC6 protein is the primary molecular defect of the disease.

hepatocyte CL:0000182

Downstream

Reduced Hepatic ATP Efflux Loss of the ABCC6 transporter abolishes its normal promotion of cellular ATP efflux.

Show evidence (1 reference)

PMID:38815804 SUPPORT Human Clinical

"Mutations in the ABCC6-gene are causative, coding for a transmembrane transporter mainly expressed in hepatocytes, which promotes the efflux of adenosine triphosphate (ATP)."

Establishes biallelic ABCC6 transporter loss as the causative molecular defect of PXE.

Reduced Hepatic ATP Efflux

Functional ABCC6 normally promotes cellular efflux of ATP from hepatocytes into the circulation. With ABCC6 loss, hepatic ATP release falls, reducing the extracellular ATP substrate available for downstream conversion.

ATP export GO:1904669 ↓ DECREASED

Downstream

Plasma Pyrophosphate Deficiency Reduced extracellular ATP lowers the substrate available for conversion to inorganic pyrophosphate.

Show evidence (1 reference)

DOI:10.3390/ijms22094555 SUPPORT Human Clinical

"ABCC6 facilitates the cellular efflux of ATP, which is rapidly converted into inorganic pyrophosphate (PPi) and adenosine by the ectonucleotidases NPP1 and CD73 (NT5E)."

Establishes ABCC6-dependent cellular ATP efflux as the step lost in PXE, feeding the NPP1/CD73 purinergic pathway.

Plasma Pyrophosphate Deficiency

Extracellular ATP is normally converted to inorganic pyrophosphate (PPi), the principal circulating anti-mineralization factor. Reduced hepatic ATP release lowers plasma PPi and the PPi/Pi ratio, removing the brake on tissue calcification.

Downstream

Ectopic Elastic Fiber Mineralization Loss of the PPi anti-mineralization brake permits calcium-phosphate deposition on elastic fibers.

Show evidence (2 references)

PMID:38815804 SUPPORT Human Clinical

"This results in low levels of plasma inorganic pyrophosphate (PPi), a critical anti-mineralization factor."

Links reduced ATP efflux to low plasma PPi, the key anti-mineralization factor.

PMID:28486967 SUPPORT Human Clinical

"There is good evidence to suggest that the factor is inorganic pyrophosphate (PPi), and that the circulating low levels of PPi and decreased PPi/Pi ratio result from the lack of ATP release by hepatocytes harboring the mutant ABCC6 protein."

Identifies low PPi and a decreased PPi/Pi ratio as the metabolic consequence of hepatic ABCC6 deficiency.

Ectopic Elastic Fiber Mineralization

Without sufficient PPi, calcium and phosphate progressively deposit on elastic fibers in the mid-dermis, Bruch membrane of the eye, and arterial walls. The affected elastic fibers become fragmented, clumped, and calcified (demonstrable on skin biopsy with a von Kossa calcium stain).

fibroblast CL:0000057

Biomineral tissue development GO:0031214 ↑ INCREASED

Downstream

Arterial Wall Calcification and Vasculopathy Mineralization of arterial elastic laminae drives the systemic vasculopathy.

Angioid Streaks Dystrophic calcification of Bruch membrane produces angioid streaks.

Choroidal Neovascularization Angioid streaks in calcified Bruch membrane can trigger choroidal neovascularization.

Reduced Vision Ocular mineralization complications cause reduced central visual acuity.

Cutaneous Papules Mineralized mid-dermal elastic fibers produce yellow papules in flexural skin.

Skin Laxity Progressive dermal elastic-fiber mineralization causes loose and wrinkled skin.

Show evidence (2 references)

PMID:28486967 SUPPORT Human Clinical

"The lack of functional ABCC6 protein leads to ectopic mineralization that is most apparent in the elastic tissues of the skin, eyes and blood vessels."

Establishes ectopic mineralization of elastic tissue in skin, eyes, and vessels as the core lesion.

PMID:28486967 SUPPORT Human Clinical

"The mid-dermal elastic fibers are short, fragmented, clumped and calcified."

Describes the characteristic calcified dystrophic elastic fibers.

Arterial Wall Calcification and Vasculopathy

Calcification of elastic fibers in small and medium-sized arteries produces a systemic vasculopathy. Luminal compromise and vessel fragility underlie peripheral arterial disease, gastrointestinal bleeding, ischemic stroke, renovascular hypertension, and cardiac ischemia.

Biomineral tissue development GO:0031214 ↑ INCREASED

Downstream

Intermittent Claudication and Peripheral Arterial Disease Small- and medium-artery lesions narrow peripheral arterial supply and cause claudication.

Arterial Calcification PXE vasculopathy is defined by calcification of arterial elastic fibers.

Cardiac Ischemia Coronary involvement in systemic PXE vasculopathy can cause angina or myocardial infarction.

Gastrointestinal Hemorrhage Vascular fragility in the digestive tract predisposes to GI bleeding.

Ischemic Stroke Cerebrovascular disease in systemic PXE vasculopathy can cause stroke.

Renovascular Hypertension Renal arterial involvement can produce renovascular hypertension.

Show evidence (2 references)

PMID:38815804 SUPPORT Human Clinical

"The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes."

Identifies the cardiovascular system as a primary target of elastic-fiber calcification.

PMID:28486967 SUPPORT Human Clinical

"Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease."

Links arterial-wall lesions to the peripheral vascular manifestations.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Blood 1

Gastrointestinal Hemorrhage Gastrointestinal hemorrhage HP:0002239

Show evidence (1 reference)

PMID:20301292 SUPPORT Human Clinical

"Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."

Lists gastrointestinal bleeding among the systemic vascular manifestations.

Cardiovascular 3

Arterial Calcification Arterial calcification HP:0003207

Show evidence (1 reference)

PMID:38815804 SUPPORT Human Clinical

"The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes."

Cardiovascular elastic-fiber calcification is a core phenotype of PXE.

Cardiac Ischemia Myocardial infarction HP:0001658

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"Cardiac complications (myocardial infarction, angina pectoris) are thought to be relatively rare but merit thorough investigation."

Documents myocardial infarction and angina as recognized cardiac complications.

Ischemic Stroke Stroke HP:0001297

Show evidence (1 reference)

PMID:20301292 SUPPORT Human Clinical

"Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."

Stroke is included among the systemic vascular manifestations of PXE.

Eye 1

Reduced Vision Reduced visual acuity HP:0007663

Show evidence (1 reference)

PMID:20301292 SUPPORT Human Clinical

"The most frequent cause of morbidity and disability in PXE is reduced vision due to complications of subretinal neovascularizations and macular atrophy."

Reduced vision from neovascular/macular complications is the principal cause of disability.

Integument 1

Skin Laxity Cutis laxa HP:0000973

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"The papules coalesce, and the skin becomes loose and wrinkled."

Lax, loose, wrinkled skin is a distinct dermatologic feature of progressed PXE.

Other 5

Angioid Streaks Angioid streaks HP:0001102

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"

Angioid streaks reflect calcification of Bruch membrane and predispose to choroidal neovascularization.

Choroidal Neovascularization Choroidal neovascularization HP:0011506

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"

Choroidal neovascularization arises from Bruch membrane calcification.

Cutaneous Papules Papule HP:0200034

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"The first clinical sign of PXE is almost always small yellow papules on the nape and sides of the neck and in flexural areas."

Yellow cutaneous papules in characteristic distribution are the usual presenting sign.

Intermittent Claudication and Peripheral Arterial Disease Intermittent claudication HP:0004417

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease."

Arterial-wall calcification produces claudication and peripheral arterial disease.

Renovascular Hypertension Renovascular hypertension HP:0100817

Show evidence (1 reference)

PMID:20301292 SUPPORT Human Clinical

"Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."

Renovascular hypertension is listed among PXE's systemic vascular manifestations.

🧬

Genetic Associations

1

ABCC6 Biallelic Loss-of-Function (Causative Gene)

Gene: ABCC6 hgnc:57 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:28486967 SUPPORT Human Clinical

"More than 300 sequence variants of the ABCC6 gene have been identified."

Documents the allelic heterogeneity of ABCC6 in PXE.

PMID:20301292 SUPPORT Human Clinical

"The molecular diagnosis of PXE is established in a proband by the presence of biallelic ABCC6 pathogenic variants"

Confirms biallelic ABCC6 variants as the molecular basis and diagnostic criterion.

💊

Medical Actions

5

Anti-VEGF Intravitreal Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: ranibizumab NCIT:C67562 bevacizumab NCIT:C2039

Intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is used to treat macular/choroidal neovascularization, the main threat to vision in PXE.

Target Phenotypes: Choroidal neovascularization HP:0011506

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"

Anti-VEGF therapy is the principal treatment for the ophthalmic (neovascular) manifestations.

Lifestyle and Dietary Modification

Category: Therapeutic Action: dietary intervention MAXO:0000088

Lifestyle and dietary measures are used to reduce modifiable vascular risk factors and limit progression of the systemic vasculopathy.

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"

Lifestyle and dietary measures target modifiable vascular risk factors.

Lipid-Lowering Therapy

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Lipid-lowering pharmacotherapy is used to reduce cardiovascular risk burden in the systemic vasculopathy of PXE.

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"

Lipid-lowering therapy is a recognized vascular-risk-reduction measure in PXE.

Vascular Surgery

Category: Therapeutic Action: surgical procedure MAXO:0000004

Vascular surgical intervention is used for symptomatic complications of the arterial disease.

Show evidence (1 reference)

PMID:28486967 SUPPORT Human Clinical

"the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"

Vascular surgery addresses symptomatic arterial complications.

Etidronate (Disease-Modifying Candidate)

Action: Pharmacotherapy NCIT:C15986

Agent: etidronate CHEBI:4907

Etidronate, an oral bisphosphonate pyrophosphate analog, is an investigational disease-modifying therapy aimed at the underlying mineralization defect. In a randomized placebo-controlled trial it reduced arterial calcification and subretinal neovascularization events, though it did not lower femoral PET mineralization activity (the primary endpoint).

Show evidence (1 reference)

PMID:29519353 SUPPORT Human Clinical

"In patients with PXE, etidronate reduced arterial calcification and subretinal neovascularization events but did not lower femoral 18fluoride sodium positron emission tomography activity compared with placebo, without important safety issues."

Randomized placebo-controlled trial evidence that etidronate reduces arterial calcification and subretinal neovascularization in PXE.

🔬

Biochemical Markers

1

Low Plasma Inorganic Pyrophosphate (PPi)

Show evidence (1 reference)

PMID:38815804 SUPPORT Human Clinical

"This results in low levels of plasma inorganic pyrophosphate (PPi), a critical anti-mineralization factor."

Low plasma PPi is the central biochemical defect underlying ectopic mineralization.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Pseudoxanthoma Elasticum:

Generalized Arterial Calcification of Infancy

Overlapping Features GACI is a severe infantile ectopic mineralization disorder, usually caused by ENPP1 deficiency, that shares the ABCC6-NPP1-CD73 pyrophosphate pathway with PXE; some GACI cases are caused by ABCC6 variants, and the two disorders form a clinical/molecular continuum.

Distinguishing Features

GACI presents with severe arterial calcification in infancy, versus adult-onset PXE
GACI is most often ENPP1-related, though ABCC6 variants can cause some cases

Show evidence (1 reference)

DOI:10.3390/ijms22094555 SUPPORT Human Clinical

"ABCC6 dysfunction is the primary cause of PXE, but also some cases of generalized arterial calcification of infancy (GACI)."

GACI shares ABCC6/pyrophosphate-pathway biology with PXE and is a key differential within the mineralization spectrum.

Calcification of Joints and Arteries (CALJA/ACDC)

Overlapping Features CALJA (arterial calcification due to CD73/NT5E deficiency, also called ACDC) is an adult-onset ectopic mineralization disorder in the same pyrophosphate- pathway spectrum as PXE, affecting joints and lower-extremity arteries.

Distinguishing Features

CALJA is caused by NT5E (CD73) deficiency rather than ABCC6
Periarticular and lower-limb arterial calcification with joint involvement

Show evidence (1 reference)

DOI:10.3390/ijms22094555 SUPPORT Human Clinical

"These calcification diseases are part of a spectrum of mineralization disorders that also includes Calcification of Joints and Arteries (CALJA)."

CALJA is part of the ectopic mineralization spectrum that includes PXE, making it a relevant differential.

{ }

Source YAML

click to show

name: Pseudoxanthoma Elasticum
creation_date: "2026-06-18T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: inherited pseudoxanthoma elasticum
  term:
    id: MONDO:0100091
    label: inherited pseudoxanthoma elasticum
parents:
- autosomal recessive disease
- rare disease
description: >
  Pseudoxanthoma elasticum (PXE) is an autosomal-recessive, multisystem ectopic
  mineralization disorder caused by biallelic loss-of-function variants in ABCC6.
  ABCC6 is a hepatocyte transmembrane transporter that promotes cellular ATP
  efflux; its loss lowers plasma inorganic pyrophosphate (PPi), the principal
  circulating anti-mineralization factor, leading to progressive calcification of
  elastic fibers in the skin, the eyes (Bruch membrane), and the cardiovascular
  system. Hallmark features are yellow skin papules, retinal angioid streaks with
  risk of vision-threatening choroidal neovascularization, and a systemic
  vasculopathy producing peripheral arterial disease, gastrointestinal bleeding,
  ischemic stroke, renovascular hypertension, and cardiac ischemia. Most patients
  have a normal life span.
synonyms:
- Gronblad-Strandberg syndrome
- PXE
prevalence:
- population: general population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.0
  percentage: 0.004
  notes: >-
    Clinical prevalence estimated between 1 in 100,000 and 1 in 25,000, with a
    slight female predominance.
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical prevalence of PXE has been estimated at between 1 per 100,000 and 1 per 25,000, with slight female predominance."
    explanation: >-
      Provides the clinical prevalence range and sex distribution of PXE.
pathophysiology:
- name: ABCC6 Transporter Loss of Function
  description: >
    PXE is caused by biallelic loss-of-function variants in ABCC6, an ATP-binding
    cassette transmembrane transporter expressed mainly in hepatocytes. Loss of
    functional ABCC6 protein is the primary molecular defect of the disease.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:38815804
    reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the ABCC6-gene are causative, coding for a transmembrane transporter mainly expressed in hepatocytes, which promotes the efflux of adenosine triphosphate (ATP)."
    explanation: >-
      Establishes biallelic ABCC6 transporter loss as the causative molecular
      defect of PXE.
  downstream:
  - target: Reduced Hepatic ATP Efflux
    causal_link_type: DIRECT
    description: >-
      Loss of the ABCC6 transporter abolishes its normal promotion of cellular
      ATP efflux.
- name: Reduced Hepatic ATP Efflux
  description: >
    Functional ABCC6 normally promotes cellular efflux of ATP from hepatocytes
    into the circulation. With ABCC6 loss, hepatic ATP release falls, reducing the
    extracellular ATP substrate available for downstream conversion.
  biological_processes:
  - preferred_term: ATP export
    term:
      id: GO:1904669
      label: ATP export
    modifier: DECREASED
  evidence:
  - reference: DOI:10.3390/ijms22094555
    reference_title: "ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ABCC6 facilitates the cellular efflux of ATP, which is rapidly converted into inorganic pyrophosphate (PPi) and adenosine by the ectonucleotidases NPP1 and CD73 (NT5E)."
    explanation: >-
      Establishes ABCC6-dependent cellular ATP efflux as the step lost in PXE,
      feeding the NPP1/CD73 purinergic pathway.
  downstream:
  - target: Plasma Pyrophosphate Deficiency
    causal_link_type: DIRECT
    description: >-
      Reduced extracellular ATP lowers the substrate available for conversion to
      inorganic pyrophosphate.
- name: Plasma Pyrophosphate Deficiency
  description: >
    Extracellular ATP is normally converted to inorganic pyrophosphate (PPi), the
    principal circulating anti-mineralization factor. Reduced hepatic ATP release
    lowers plasma PPi and the PPi/Pi ratio, removing the brake on tissue
    calcification.
  evidence:
  - reference: PMID:38815804
    reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This results in low levels of plasma inorganic pyrophosphate (PPi), a critical anti-mineralization factor."
    explanation: >-
      Links reduced ATP efflux to low plasma PPi, the key anti-mineralization
      factor.
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is good evidence to suggest that the factor is inorganic pyrophosphate (PPi), and that the circulating low levels of PPi and decreased PPi/Pi ratio result from the lack of ATP release by hepatocytes harboring the mutant ABCC6 protein."
    explanation: >-
      Identifies low PPi and a decreased PPi/Pi ratio as the metabolic
      consequence of hepatic ABCC6 deficiency.
  downstream:
  - target: Ectopic Elastic Fiber Mineralization
    causal_link_type: DIRECT
    description: >-
      Loss of the PPi anti-mineralization brake permits calcium-phosphate
      deposition on elastic fibers.
- name: Ectopic Elastic Fiber Mineralization
  description: >
    Without sufficient PPi, calcium and phosphate progressively deposit on
    elastic fibers in the mid-dermis, Bruch membrane of the eye, and arterial
    walls. The affected elastic fibers become fragmented, clumped, and calcified
    (demonstrable on skin biopsy with a von Kossa calcium stain).
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: Biomineral tissue development
    term:
      id: GO:0031214
      label: biomineral tissue development
    modifier: INCREASED
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lack of functional ABCC6 protein leads to ectopic mineralization that is most apparent in the elastic tissues of the skin, eyes and blood vessels."
    explanation: >-
      Establishes ectopic mineralization of elastic tissue in skin, eyes, and
      vessels as the core lesion.
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mid-dermal elastic fibers are short, fragmented, clumped and calcified."
    explanation: >-
      Describes the characteristic calcified dystrophic elastic fibers.
  downstream:
  - target: Arterial Wall Calcification and Vasculopathy
    causal_link_type: DIRECT
    description: >-
      Mineralization of arterial elastic laminae drives the systemic vasculopathy.
  - target: Angioid Streaks
    causal_link_type: DIRECT
    description: Dystrophic calcification of Bruch membrane produces angioid streaks.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"
      explanation: The review directly links Bruch membrane calcification to angioid streaks.
  - target: Choroidal Neovascularization
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Angioid streaks in calcified Bruch membrane
    description: Angioid streaks in calcified Bruch membrane can trigger choroidal neovascularization.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"
      explanation: The review directly links Bruch membrane calcification and angioid streaks to choroidal neovascularization.
  - target: Reduced Vision
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Subretinal neovascularization
    - Macular atrophy
    description: Ocular mineralization complications cause reduced central visual acuity.
    evidence:
    - reference: PMID:20301292
      reference_title: "Pseudoxanthoma Elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most frequent cause of morbidity and disability in PXE is reduced vision due to complications of subretinal neovascularizations and macular atrophy."
      explanation: GeneReviews links PXE ocular complications to reduced vision.
  - target: Cutaneous Papules
    causal_link_type: DIRECT
    description: Mineralized mid-dermal elastic fibers produce yellow papules in flexural skin.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The first clinical sign of PXE is almost always small yellow papules on the nape and sides of the neck and in flexural areas."
      explanation: The review identifies yellow papules as the usual first clinical sign.
  - target: Skin Laxity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Coalescing cutaneous papules
    description: Progressive dermal elastic-fiber mineralization causes loose and wrinkled skin.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The papules coalesce, and the skin becomes loose and wrinkled."
      explanation: The review links coalescing papules to loose, wrinkled skin.
- name: Arterial Wall Calcification and Vasculopathy
  description: >
    Calcification of elastic fibers in small and medium-sized arteries produces a
    systemic vasculopathy. Luminal compromise and vessel fragility underlie
    peripheral arterial disease, gastrointestinal bleeding, ischemic stroke,
    renovascular hypertension, and cardiac ischemia.
  biological_processes:
  - preferred_term: Biomineral tissue development
    term:
      id: GO:0031214
      label: biomineral tissue development
    modifier: INCREASED
  evidence:
  - reference: PMID:38815804
    reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes."
    explanation: >-
      Identifies the cardiovascular system as a primary target of elastic-fiber
      calcification.
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease."
    explanation: >-
      Links arterial-wall lesions to the peripheral vascular manifestations.
  downstream:
  - target: Intermittent Claudication and Peripheral Arterial Disease
    causal_link_type: DIRECT
    description: Small- and medium-artery lesions narrow peripheral arterial supply and cause claudication.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease."
      explanation: The review directly links arterial-wall lesions to claudication and peripheral artery disease.
  - target: Arterial Calcification
    causal_link_type: DIRECT
    description: PXE vasculopathy is defined by calcification of arterial elastic fibers.
    evidence:
    - reference: PMID:38815804
      reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes."
      explanation: The review identifies cardiovascular elastic-fiber calcification as a core PXE phenotype.
  - target: Cardiac Ischemia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Coronary arterial involvement
    description: Coronary involvement in systemic PXE vasculopathy can cause angina or myocardial infarction.
    evidence:
    - reference: PMID:28486967
      reference_title: "Pseudoxanthoma elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cardiac complications (myocardial infarction, angina pectoris) are thought to be relatively rare but merit thorough investigation."
      explanation: The review documents myocardial infarction and angina as PXE cardiac complications.
  - target: Gastrointestinal Hemorrhage
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Gastrointestinal vascular fragility
    description: Vascular fragility in the digestive tract predisposes to GI bleeding.
    evidence:
    - reference: PMID:20301292
      reference_title: "Pseudoxanthoma Elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
      explanation: GeneReviews lists GI bleeding among systemic vascular manifestations.
  - target: Ischemic Stroke
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Cerebrovascular involvement
    description: Cerebrovascular disease in systemic PXE vasculopathy can cause stroke.
    evidence:
    - reference: PMID:20301292
      reference_title: "Pseudoxanthoma Elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
      explanation: GeneReviews lists stroke among systemic vascular manifestations.
  - target: Renovascular Hypertension
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Renal arterial involvement
    description: Renal arterial involvement can produce renovascular hypertension.
    evidence:
    - reference: PMID:20301292
      reference_title: "Pseudoxanthoma Elasticum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
      explanation: GeneReviews lists renovascular hypertension among systemic vascular manifestations.
phenotypes:
- category: Ophthalmologic
  name: Angioid Streaks
  description: >
    Breaks in the calcified, brittle Bruch membrane produce angioid streaks, a
    characteristic ocular sign that can trigger choroidal neovascularization.
  phenotype_term:
    preferred_term: Angioid streaks
    term:
      id: HP:0001102
      label: Angioid streaks
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"
    explanation: >-
      Angioid streaks reflect calcification of Bruch membrane and predispose to
      choroidal neovascularization.
- category: Ophthalmologic
  name: Choroidal Neovascularization
  description: >
    Secondary choroidal neovascularization with macular complications is the
    leading cause of central vision loss in PXE.
  phenotype_term:
    preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystrophic calcification of Bruch's membrane, revealed by angioid streaks, may trigger choroidal neovascularization"
    explanation: >-
      Choroidal neovascularization arises from Bruch membrane calcification.
- category: Ophthalmologic
  name: Reduced Vision
  description: >
    Subretinal neovascularization and macular atrophy reduce visual acuity and
    are the most frequent cause of morbidity and disability in PXE.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent cause of morbidity and disability in PXE is reduced vision due to complications of subretinal neovascularizations and macular atrophy."
    explanation: >-
      Reduced vision from neovascular/macular complications is the principal
      cause of disability.
- category: Dermatologic
  name: Cutaneous Papules
  description: >
    Small yellow papules on the nape and lateral neck and in flexural areas are
    typically the first clinical sign; they coalesce, and the skin becomes loose
    and wrinkled.
  phenotype_term:
    preferred_term: Papule
    term:
      id: HP:0200034
      label: Papule
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first clinical sign of PXE is almost always small yellow papules on the nape and sides of the neck and in flexural areas."
    explanation: >-
      Yellow cutaneous papules in characteristic distribution are the usual
      presenting sign.
- category: Dermatologic
  name: Skin Laxity
  description: >
    With disease progression the coalescing papules give way to lax, loose, and
    wrinkled skin in affected flexural areas, a characteristic feature of
    established PXE.
  phenotype_term:
    preferred_term: Skin laxity
    term:
      id: HP:0000973
      label: Cutis laxa
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The papules coalesce, and the skin becomes loose and wrinkled."
    explanation: >-
      Lax, loose, wrinkled skin is a distinct dermatologic feature of progressed
      PXE.
- category: Cardiovascular
  name: Intermittent Claudication and Peripheral Arterial Disease
  description: >
    Calcific lesions of small and medium-sized arteries cause peripheral arterial
    disease with intermittent claudication of the arm and leg muscles.
  phenotype_term:
    preferred_term: Intermittent claudication
    term:
      id: HP:0004417
      label: Intermittent claudication
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease."
    explanation: >-
      Arterial-wall calcification produces claudication and peripheral arterial
      disease.
- category: Cardiovascular
  name: Arterial Calcification
  description: >
    Calcification of elastic fibers within arterial walls is a defining
    cardiovascular feature of PXE.
  phenotype_term:
    preferred_term: Arterial calcification
    term:
      id: HP:0003207
      label: Arterial calcification
  evidence:
  - reference: PMID:38815804
    reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes."
    explanation: >-
      Cardiovascular elastic-fiber calcification is a core phenotype of PXE.
- category: Cardiovascular
  name: Cardiac Ischemia
  description: >
    Coronary involvement can produce angina pectoris and myocardial infarction;
    cardiac complications are considered relatively uncommon but clinically
    important.
  phenotype_term:
    preferred_term: Myocardial infarction
    term:
      id: HP:0001658
      label: Myocardial infarction
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cardiac complications (myocardial infarction, angina pectoris) are thought to be relatively rare but merit thorough investigation."
    explanation: >-
      Documents myocardial infarction and angina as recognized cardiac
      complications.
- category: Gastrointestinal
  name: Gastrointestinal Hemorrhage
  description: >
    Vascular fragility predisposes to premature gastrointestinal angina and
    bleeding, particularly from the upper gastrointestinal tract.
  phenotype_term:
    preferred_term: Gastrointestinal hemorrhage
    term:
      id: HP:0002239
      label: Gastrointestinal hemorrhage
  evidence:
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
    explanation: >-
      Lists gastrointestinal bleeding among the systemic vascular manifestations.
- category: Neurologic
  name: Ischemic Stroke
  description: >
    Cerebrovascular involvement can cause ischemic stroke as part of the systemic
    vasculopathy.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
    explanation: >-
      Stroke is included among the systemic vascular manifestations of PXE.
- category: Renal
  name: Renovascular Hypertension
  description: >
    Calcific renal arterial disease can produce renovascular hypertension.
  phenotype_term:
    preferred_term: Renovascular hypertension
    term:
      id: HP:0100817
      label: Renovascular hypertension
  evidence:
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction)."
    explanation: >-
      Renovascular hypertension is listed among PXE's systemic vascular
      manifestations.
biochemical:
- name: Low Plasma Inorganic Pyrophosphate (PPi)
  notes: >-
    Reduced plasma inorganic pyrophosphate and a decreased PPi/Pi ratio are the
    characteristic biochemical abnormality, reflecting deficient hepatic ATP
    release.
  evidence:
  - reference: PMID:38815804
    reference_title: "Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This results in low levels of plasma inorganic pyrophosphate (PPi), a critical anti-mineralization factor."
    explanation: >-
      Low plasma PPi is the central biochemical defect underlying ectopic
      mineralization.
genetic:
- name: ABCC6 Biallelic Loss-of-Function
  gene_term:
    preferred_term: ABCC6
    term:
      id: hgnc:57
      label: ABCC6
  association: Causative Gene
  variant_origin: GERMLINE
  relationship_type: CAUSATIVE
  notes: >-
    PXE is caused by biallelic pathogenic variants in ABCC6 (OMIM 264800); more
    than 300 sequence variants have been described. The nonsense variant p.R1141X
    and a recurrent large deletion of exons 23-29 are among the most frequent
    pathogenic alleles. Sequencing is complicated by the ABCC6 pseudogenes
    (ABCC6P1/ABCC6P2) that share high sequence identity with the 5' region of the
    gene. Molecular diagnosis rests on identifying biallelic ABCC6 variants.
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 300 sequence variants of the ABCC6 gene have been identified."
    explanation: >-
      Documents the allelic heterogeneity of ABCC6 in PXE.
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The molecular diagnosis of PXE is established in a proband by the presence of biallelic ABCC6 pathogenic variants"
    explanation: >-
      Confirms biallelic ABCC6 variants as the molecular basis and diagnostic
      criterion.
treatments:
- name: Anti-VEGF Intravitreal Therapy
  description: >
    Intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is
    used to treat macular/choroidal neovascularization, the main threat to vision
    in PXE.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ranibizumab
      term:
        id: NCIT:C67562
        label: Ranibizumab
    - preferred_term: bevacizumab
      term:
        id: NCIT:C2039
        label: Bevacizumab
  target_phenotypes:
  - preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"
    explanation: >-
      Anti-VEGF therapy is the principal treatment for the ophthalmic
      (neovascular) manifestations.
- name: Lifestyle and Dietary Modification
  description: >
    Lifestyle and dietary measures are used to reduce modifiable vascular risk
    factors and limit progression of the systemic vasculopathy.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"
    explanation: >-
      Lifestyle and dietary measures target modifiable vascular risk factors.
- name: Lipid-Lowering Therapy
  description: >
    Lipid-lowering pharmacotherapy is used to reduce cardiovascular risk burden
    in the systemic vasculopathy of PXE.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"
    explanation: >-
      Lipid-lowering therapy is a recognized vascular-risk-reduction measure in
      PXE.
- name: Vascular Surgery
  description: >
    Vascular surgical intervention is used for symptomatic complications of the
    arterial disease.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:28486967
    reference_title: "Pseudoxanthoma elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery"
    explanation: >-
      Vascular surgery addresses symptomatic arterial complications.
- name: Etidronate (Disease-Modifying Candidate)
  description: >
    Etidronate, an oral bisphosphonate pyrophosphate analog, is an investigational
    disease-modifying therapy aimed at the underlying mineralization defect. In a
    randomized placebo-controlled trial it reduced arterial calcification and
    subretinal neovascularization events, though it did not lower femoral PET
    mineralization activity (the primary endpoint).
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: etidronate
      term:
        id: CHEBI:4907
        label: etidronic acid
  evidence:
  - reference: PMID:29519353
    reference_title: "Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with PXE, etidronate reduced arterial calcification and subretinal neovascularization events but did not lower femoral 18fluoride sodium positron emission tomography activity compared with placebo, without important safety issues."
    explanation: >-
      Randomized placebo-controlled trial evidence that etidronate reduces
      arterial calcification and subretinal neovascularization in PXE.
progression:
- phase: Natural history
  notes: >-
    PXE is slowly progressive; skin papules are typically the first sign, ocular
    and vascular complications accrue over time, and most affected individuals
    have a normal life span.
  evidence:
  - reference: PMID:20301292
    reference_title: "Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most affected individuals live a normal life span."
    explanation: >-
      Despite multisystem morbidity, overall life span is typically normal.
differential_diagnoses:
- name: Generalized Arterial Calcification of Infancy
  description: >-
    GACI is a severe infantile ectopic mineralization disorder, usually caused by
    ENPP1 deficiency, that shares the ABCC6-NPP1-CD73 pyrophosphate pathway with
    PXE; some GACI cases are caused by ABCC6 variants, and the two disorders form
    a clinical/molecular continuum.
  distinguishing_features:
  - GACI presents with severe arterial calcification in infancy, versus adult-onset PXE
  - GACI is most often ENPP1-related, though ABCC6 variants can cause some cases
  evidence:
  - reference: DOI:10.3390/ijms22094555
    reference_title: "ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ABCC6 dysfunction is the primary cause of PXE, but also some cases of generalized arterial calcification of infancy (GACI)."
    explanation: >-
      GACI shares ABCC6/pyrophosphate-pathway biology with PXE and is a key
      differential within the mineralization spectrum.
- name: Calcification of Joints and Arteries (CALJA/ACDC)
  description: >-
    CALJA (arterial calcification due to CD73/NT5E deficiency, also called ACDC)
    is an adult-onset ectopic mineralization disorder in the same pyrophosphate-
    pathway spectrum as PXE, affecting joints and lower-extremity arteries.
  distinguishing_features:
  - CALJA is caused by NT5E (CD73) deficiency rather than ABCC6
  - Periarticular and lower-limb arterial calcification with joint involvement
  evidence:
  - reference: DOI:10.3390/ijms22094555
    reference_title: "ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These calcification diseases are part of a spectrum of mineralization disorders that also includes Calcification of Joints and Arteries (CALJA)."
    explanation: >-
      CALJA is part of the ectopic mineralization spectrum that includes PXE,
      making it a relevant differential.
discussions:
- discussion_id: gap_pxe_disease_modifying_therapy
  prompt: >-
    Can a disease-modifying therapy that durably restores the pyrophosphate
    anti-mineralization brake (e.g., bisphosphonate pyrophosphate analogs,
    recombinant ENPP1, or ABCC6-directed gene therapy) be established for PXE,
    given that current care is only symptomatic?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Plasma Pyrophosphate Deficiency
  rationale: >-
    PXE is mechanistically a PPi-deficiency disorder, yet approved therapies only
    alleviate symptoms. Etidronate reduced calcification and neovascularization in
    a randomized trial but missed its primary PET endpoint, and pathway-restoring
    agents (recombinant ENPP1, gene therapy) remain preclinical, leaving a clear
    unmet need for a proven disease-modifying treatment.
  evidence:
  - reference: DOI:10.3390/ijms22094555
    reference_title: "ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At present, therapies only exist to alleviate symptoms for both PXE and GACI"
    explanation: >-
      Confirms that only symptomatic therapy currently exists, defining the
      disease-modifying-treatment gap.
  - reference: PMID:29519353
    reference_title: "Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with PXE, etidronate reduced arterial calcification and subretinal neovascularization events but did not lower femoral 18fluoride sodium positron emission tomography activity compared with placebo, without important safety issues."
    explanation: >-
      Etidronate shows partial disease-modifying activity but missed its primary
      endpoint, illustrating the unresolved therapeutic gap.
references:
- reference: PMID:20301292
  title: "Pseudoxanthoma Elasticum."
  tags:
  - GeneReviews

📚

References & Deep Research

References

1

PMID:20301292

Pseudoxanthoma Elasticum.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 32 citations 2026-06-18T22:30:22.311763

1. Disease Information

Disease Definition and Overview

Pseudoxanthoma elasticum (PXE; OMIM #264800) is a rare, genetic, autosomal recessive metabolic disease characterized by progressive ectopic mineralization affecting elastic tissues in the skin, eyes, and cardiovascular system (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2). The disease manifests with deposition of calcium hydroxyapatite crystals that accumulate in the mid-dermal elastic fibers, Bruch's membrane of the eye, and arterial blood vessels (luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2). PXE is the prototype of heritable ectopic mineralization disorders, distinguished by its multisystem clinical manifestations that usually appear around the second decade of life (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 1-2).

Key Identifiers

OMIM: #264800 (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2)
Orphanet: ORPHA #758 (germain2017pseudoxanthomaelasticum pages 1-2)
ICD-10: Q82.8 (germain2017pseudoxanthomaelasticum pages 1-2)
Alternative Names: Grönblad-Strandberg syndrome (germain2017pseudoxanthomaelasticum pages 1-2, marconi2015pseudoxanthomaelasticumand pages 1-2)
MONDO ID: Not explicitly provided in retrieved literature

Data Source Classification

Information is derived from aggregated disease-level resources including peer-reviewed clinical studies, systematic reviews, case series, and controlled clinical trials in PXE patient cohorts, complemented by animal model research and cellular studies (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, kranenburg2018etidronateforprevention pages 1-2).

2. Etiology

Disease Causal Factors

PXE is a genetic disorder caused by mutations in the ABCC6 gene (ATP-binding cassette subfamily C member 6), discovered in 2000 (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). The ABCC6 gene is located on chromosome 16p13.11 and consists of 31 exons encoding a 1503-amino acid protein (molecular weight approximately 165–170 kDa) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). ABCC6 functions as an ATP-dependent transmembrane efflux transporter expressed predominantly in the liver and kidneys (stumpf2021therapyofpseudoxanthoma pages 1-2, kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 1-5). Although the precise substrate(s) of ABCC6 remain uncertain, it facilitates the cellular efflux of ATP, which is sequentially hydrolyzed by ectonucleotidases ENPP1 and CD73 into pyrophosphate (PPi) and adenosine, both potent endogenous inhibitors of calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

The unifying pathomechanistic feature of PXE is reduced plasma levels of inorganic pyrophosphate (PPi), a powerful anti-mineralization factor. ABCC6 deficiency leads to approximately 60% reduction in plasma PPi levels in both humans and mice (leftheriotis2022relationshipsbetweenplasma pages 1-2, zedde2025abcc6involvementin pages 1-2, verschuere2020frommembraneto pages 8-10). This PPi deficiency results in an imbalance of the physiological Pi/PPi ratio in connective tissues, promoting ectopic calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

Risk Factors

Genetic Risk Factors: - Biallelic pathogenic variants in ABCC6 are the primary genetic cause. Over 300 distinct loss-of-function mutations have been reported, with recurrent variants p.R1141X and g.del23-29 accounting for up to ~45% of all pathogenic mutations (li2019pseudoxanthomaelasticumas pages 1-6, marconi2015pseudoxanthomaelasticumand pages 1-2, plumers2023matrixmetalloproteinasescontribute pages 1-2). - Variant types include missense, nonsense, frameshift, splice-site mutations, and structural rearrangements (deletions, duplications) (marconi2015pseudoxanthomaelasticumand pages 1-2, verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5). - Rare modifier variants in genes related to calcium homeostasis, vascular disease, apoptosis, and purinergic signaling (e.g., NLRP1, SELE, TRPV1, CSF1R) may alter cardiovascular disease severity (vilder2021raremodifiervariants pages 1-2). - Heterozygous carriers of ABCC6 mutations may have an increased risk of cardiovascular calcification and premature coronary artery disease, although classic PXE typically requires biallelic pathogenic variants (germain2017pseudoxanthomaelasticum pages 2-4, germain2017pseudoxanthomaelasticum pages 4-5).

Environmental Risk Factors: - Age is a major determinant of disease severity and calcification burden; time (i.e., age) appears to be the principal driver of progressive arterial calcification independent of plasma PPi levels (leftheriotis2022relationshipsbetweenplasma pages 1-2). - Traditional cardiovascular risk factors such as smoking, dyslipidemia, and hypertension may additively worsen vascular complications (stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2).

Protective Factors

Specific genetic protective factors have not been definitively established in retrieved literature. However, higher serum magnesium levels were associated with higher serum calcification propensity T50 (indicative of lower calcification risk), suggesting magnesium may have a protective role (nollet2022serumcalcificationpropensity pages 1-2). Lifestyle modifications reducing cardiovascular risk factors are recommended as supportive measures but do not reverse underlying mineralization (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2).

Gene-Environment Interactions

PXE pathophysiology reflects a complex interplay between genetic ABCC6 deficiency and environmental/age-related factors. While ABCC6 mutations cause systemic PPi deficiency, environmental contributors such as dietary phosphate, oxidative stress, and aging accelerate or modulate the mineralization process (germain2017pseudoxanthomaelasticum pages 4-5). Specific gene-environment interaction data are limited in retrieved studies.

3. Phenotypes

Organ System	Specific Manifestation	Age of Onset	Frequency in PXE Patients	Severity	Progression Pattern	HPO Terms (suggested)	Quality of Life Impact
Integumentary / Skin	Small yellow papules on neck and flexural areas	Typically childhood to adolescence; often first clinical sign (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Common / usually initial presenting sign; “almost always” first clinical sign in review literature (germain2017pseudoxanthomaelasticum pages 1-2)	Usually mild medically, cosmetically significant	Progressive: isolated papules coalesce into plaques over time (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4)	HP:0000987 Skin papule; HP:0010783 Abnormality of the skin of the neck; HP:0000978 Bruising susceptibility not applicable; HP:0001065 Generalized lax skin not initial	Cosmetic burden; may cause distress and social/self-image impact, but usually less disabling than ocular/vascular disease (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2)
Integumentary / Skin	Lax, wrinkled, redundant skin in flexural areas	Usually follows papules, often from adolescence/early adulthood onward (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Common in established disease; qualitative frequency high in clinical descriptions (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	Mild to moderate	Progressive chronic change with loss of recoil and leathery/sagging skin (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4)	HP:0000973 Wrinkled skin; HP:0001007 Redundant skin; HP:0001513 Cutis laxa-like skin changes	Mainly cosmetic and psychosocial impact; may affect body image and clothing comfort (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2)
Ophthalmologic	Peau d’orange / early Bruch’s membrane change	Often precedes angioid streaks; can occur in young patients	Observed in 96% of patients with skin signs in one study cited by review (germain2017pseudoxanthomaelasticum pages 2-4)	Usually mild initially	Early marker that may precede more vision-threatening retinal disease (germain2017pseudoxanthomaelasticum pages 2-4, risseeuw2020areflectivitymeasure pages 1-2)	HP:0030937 Abnormality of Bruch membrane; HP:0100012 Retinal abnormality	Usually limited direct impact initially, but clinically important as precursor of later visual morbidity (germain2017pseudoxanthomaelasticum pages 2-4, risseeuw2020areflectivitymeasure pages 1-2)
Ophthalmologic	Angioid streaks	Usually years after skin changes; often early adult life (germain2017pseudoxanthomaelasticum pages 2-4)	Characteristic ocular feature; common in affected adults (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Moderate to severe because of risk of CNV and vision loss	Progressive; may become symptomatic when approaching fovea (germain2017pseudoxanthomaelasticum pages 2-4)	HP:0007932 Angioid streaks of the fundus	Major threat to vision; central visual tasks and reading/driving may become impaired (germain2017pseudoxanthomaelasticum pages 2-4)
Ophthalmologic	Choroidal neovascularization (CNV)	Usually after angioid streaks, often adulthood	Common complication of calcified Bruch’s membrane in progressing disease; exact percentage not given in retrieved sources (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	Severe	Progressive/episodic with hemorrhage and scarring if untreated (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4)	HP:0007754 Choroidal neovascularization	High impact; anti-VEGF treatment burden and risk of central vision loss reduce daily functioning (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)
Ophthalmologic	Progressive loss of visual acuity / central vision loss / blindness in late-stage disease	Often adulthood, with severe impairment potentially by 40s if untreated (luo2020therapeuticsdevelopmentfor pages 1-3)	Important late complication; exact prevalence not provided in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	Severe	Progressive due to hemorrhage, scarring, and macular atrophy (luo2020therapeuticsdevelopmentfor pages 1-3, risseeuw2020areflectivitymeasure pages 1-2)	HP:0000505 Visual impairment; HP:0000529 Progressive visual loss; HP:0000618 Blindness	Very high impact; vision-related quality of life is markedly reduced, and visual impairment was associated with major degradation in vision-related QoL (germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular	Arterial calcification (including lower-limb and coronary calcification)	Usually becomes apparent years after skin/ocular changes; increases with age (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Common hallmark in adult PXE; severity strongly age-dependent (leftheriotis2022relationshipsbetweenplasma pages 1-2, kranenburg2018etidronateforprevention pages 1-2)	Moderate to severe	Progressive, chronic, age-related accumulation; major determinant appears to be time/age (leftheriotis2022relationshipsbetweenplasma pages 1-2)	HP:0004958 Arterial calcification; HP:0005117 Vascular calcification	Contributes to vascular morbidity, reduced exercise capacity, and anxiety about cardiovascular events (stumpf2021therapyofpseudoxanthoma pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2)
Cardiovascular / Vascular	Peripheral artery disease (PAD)	Typically adulthood after earlier skin/eye findings (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Major cause of morbidity; common qualitative feature (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)	Moderate to severe	Progressive chronic vascular disease; may require intervention in advanced stages (vilder2021raremodifiervariants pages 1-2)	HP:0004939 Peripheral arterial insufficiency	Limits walking and physical activity; contributes to reduced participation in social/occupational activities (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular	Intermittent claudication	Usually adulthood	Cardinal symptom of lower-extremity arterial disease; common qualitative feature (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4)	Moderate	Progressive with worsening PAD; exertional symptom burden (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4)	HP:0002579 Intermittent claudication	Substantial mobility limitation and exercise intolerance; important contributor to reduced QoL (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular	Hypertension	Usually adulthood	Reported but less consistently emphasized than calcification/PAD; exact percentage not provided (luo2020therapeuticsdevelopmentfor pages 1-3, plumers2023matrixmetalloproteinasescontribute pages 1-2)	Mild to moderate, can contribute to vascular risk	Chronic; may coexist with arterial disease (plumers2023matrixmetalloproteinasescontribute pages 1-2)	HP:0000822 Hypertension	Adds long-term cardiovascular risk and treatment burden (luo2020therapeuticsdevelopmentfor pages 1-3, plumers2023matrixmetalloproteinasescontribute pages 1-2)
Neurologic / Cerebrovascular	Ischemic stroke risk / cerebrovascular disease	Usually older adults; risk appears elevated relative to general population (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2)	15% in one cohort of 38 PXE patients; 7% in another cohort of 100, relative risk 3.6 vs general population (germain2017pseudoxanthomaelasticum pages 2-4)	Severe	Episodic vascular complication on background of progressive vasculopathy (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2)	HP:0002140 Ischemic stroke; HP:0001297 Cerebrovascular accident	Potentially devastating disability; major anxiety source and contributor to long-term morbidity (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2)
Gastrointestinal	Gastrointestinal bleeding (especially stomach)	Usually adulthood	Around 15% of PXE patients vs ~0.1% in general population, according to review summary (germain2017pseudoxanthomaelasticum pages 2-4)	Moderate to severe; potentially acute	Episodic complication	HP:0002239 Gastrointestinal hemorrhage; HP:0002573 Hematemesis if present	Acute morbidity, hospitalization risk, and anxiety regarding bleeding events (germain2017pseudoxanthomaelasticum pages 2-4)

Table: This table summarizes the major clinical manifestations of pseudoxanthoma elasticum across skin, ocular, vascular, neurologic, and gastrointestinal systems. It highlights onset, frequency, progression, suggested HPO annotations, and likely quality-of-life effects for knowledge base curation.

The table above summarizes the major clinical manifestations across organ systems. Key phenotypes include:

Cutaneous Manifestations

Small yellow papules on the neck and flexural areas (axillae, antecubital fossae, inguinal regions), typically the first clinical sign appearing in childhood or adolescence (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Lax, wrinkled, redundant skin with loss of elasticity, giving a cobblestone or peau d'orange appearance (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4).
HPO Terms: HP:0000987 (Skin papule), HP:0000973 (Wrinkled skin), HP:0001007 (Redundant skin).

Ophthalmological Manifestations

Peau d'orange retinal changes often precede angioid streaks; observed in 96% of patients with skin signs (germain2017pseudoxanthomaelasticum pages 2-4).
Angioid streaks reflecting breaks in calcified Bruch's membrane, characteristic of PXE (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Choroidal neovascularization (CNV) leading to hemorrhage, scarring, and progressive central vision loss if untreated (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4).
Visual impairment and blindness in late-stage disease, typically by the 40s without treatment (luo2020therapeuticsdevelopmentfor pages 1-3).
HPO Terms: HP:0007932 (Angioid streaks of the fundus), HP:0007754 (Choroidal neovascularization), HP:0000505 (Visual impairment), HP:0000529 (Progressive visual loss).

Cardiovascular and Vascular Manifestations

Arterial calcification affecting medium and small arteries, strongly age-dependent (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4, kranenburg2018etidronateforprevention pages 1-2).
Peripheral artery disease (PAD) with intermittent claudication as the cardinal symptom (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4).
Hypertension (luo2020therapeuticsdevelopmentfor pages 1-3, plumers2023matrixmetalloproteinasescontribute pages 1-2).
Ischemic stroke risk elevated relative to general population; 15% in one cohort of 38 patients, 7% in another cohort of 100 (relative risk 3.6 vs general population) (germain2017pseudoxanthomaelasticum pages 2-4).
HPO Terms: HP:0004958 (Arterial calcification), HP:0004939 (Peripheral arterial insufficiency), HP:0002579 (Intermittent claudication), HP:0002140 (Ischemic stroke), HP:0000822 (Hypertension).

Gastrointestinal Manifestations

Gastrointestinal bleeding, especially from the stomach, occurs in approximately 15% of PXE patients versus ~0.1% in the general population (germain2017pseudoxanthomaelasticum pages 2-4).
HPO Terms: HP:0002239 (Gastrointestinal hemorrhage).

Quality of Life Impact

Visual impairment is associated with major degradation in vision-related quality of life measured by the Impact of Vision Impairment questionnaire (germain2017pseudoxanthomaelasticum pages 2-4). Cardiovascular complications have relatively less measured impact on health-related QoL according to SF-36 surveys, though intermittent claudication significantly limits mobility and social/occupational participation (germain2017pseudoxanthomaelasticum pages 2-4, stumpf2021therapyofpseudoxanthoma pages 1-2).

4. Genetic/Molecular Information

Gene Name	Gene Symbol	Chromosome Location	Protein Name	Protein Size	Protein Function	Common Pathogenic Variants	Variant Types	Mode of Inheritance	Penetrance	Key Molecular Pathways
ATP-binding cassette subfamily C member 6	ABCC6	16p13.11 / 16p13.1	ABCC6 / MRP6	1503 aa, ~165–170 kDa glycoprotein	ATP-dependent transmembrane efflux transporter, expressed predominantly in liver and kidney; promotes extracellular ATP efflux, which is converted by ENPP1 and CD73 to PPi and adenosine; major upstream regulator of anti-mineralization homeostasis (verschuere2020frommembraneto pages 1-5, germain2017pseudoxanthomaelasticum pages 1-2, verschuere2020frommembraneto pages 8-10, kauffenstein2024thepurinergicnature pages 1-2)	Recurrent loss-of-function variants include p.R1141X and del23-29 / g.del23-29, together accounting for up to ~45% of pathogenic alleles in some cohorts; >300 variants reported overall, now ~400 in newer summaries (li2019pseudoxanthomaelasticumas pages 1-6, marconi2015pseudoxanthomaelasticumand pages 1-2, plumers2023matrixmetalloproteinasescontribute pages 1-2)	Missense, nonsense, splice-site, small insertions/deletions, multiexon deletions/structural variants; predominantly loss-of-function (marconi2015pseudoxanthomaelasticumand pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5, verschuere2020frommembraneto pages 8-10)	Autosomal recessive PXE; ABCC6 variants can also cause some GACI type 2 cases (germain2017pseudoxanthomaelasticum pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Generally high for biallelic pathogenic variants with age-dependent and variable expressivity; heterozygotes usually unaffected but may show subclinical or partial manifestations and elevated vascular calcification risk in some reports (germain2017pseudoxanthomaelasticum pages 4-5, germain2017pseudoxanthomaelasticum pages 2-4)	ABCC6 → extracellular ATP efflux → ENPP1 → PPi + AMP → CD73/NT5E → adenosine; TNAP opposes PPi by hydrolysis; purinergic signaling / Pi:PPi balance / ectopic calcification inhibition (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, verschuere2020frommembraneto pages 8-10)
Ectonucleotide pyrophosphatase/phosphodiesterase 1	ENPP1	Not specified in retrieved PXE contexts	ENPP1 / NPP1	Not specified in retrieved PXE contexts	Principal ectoenzyme generating extracellular PPi from ATP; core anti-calcification enzyme downstream of ABCC6. ENPP1 deficiency causes classic GACI, and some ENPP1-mutated patients can present PXE-like features or overlap phenotypes (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, kauffenstein2024thepurinergicnature pages 1-2)	Specific recurrent ENPP1 variants were not detailed in retrieved PXE contexts; disease-causing ENPP1 variants underlie most classic GACI and can overlap phenotypically with PXE (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Loss-of-function variants, including missense, nonsense, splice, and other disruptive alleles causing reduced/absent ENPP1 activity; exact spectrum not detailed in retrieved contexts (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Autosomal recessive for GACI; overlap with PXE spectrum recognized (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	High for biallelic ENPP1 deficiency, but phenotype may range from severe infantile vascular calcification to PXE-like overlap; detailed penetrance not specified in retrieved contexts (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Extracellular ATP hydrolysis to AMP + PPi; central PPi-generating step in the ABCC6–ENPP1–CD73–TNAP pathway regulating ectopic mineralization (kauffenstein2024thepurinergicnature pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)
5'-nucleotidase ecto / CD73	NT5E	Not specified in retrieved PXE contexts	CD73	Not specified in retrieved PXE contexts	Converts AMP to adenosine in the extracellular space; adenosine indirectly inhibits calcification, in part by suppressing TNAP, thereby preserving PPi-mediated anti-calcification effects (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Specific recurrent NT5E pathogenic variants were not detailed in retrieved PXE contexts; NT5E mutations cause CALJA/ACDC, an overlapping ectopic calcification disorder (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Loss-of-function variants causing reduced/absent CD73 activity; exact variant spectrum not detailed in retrieved contexts (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Autosomal recessive for CALJA/ACDC; part of the PXE–GACI–CALJA disease continuum (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Detailed penetrance not specified in retrieved PXE contexts; phenotype is generally adult/late-onset in CALJA compared with PXE and GACI (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	AMP → adenosine, with downstream reduction of TNAP activity and support of anti-mineralization purinergic signaling; final shared branch of the ABCC6–ENPP1–CD73–TNAP axis (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)

Table: This table summarizes the core genes and pathway biology relevant to pseudoxanthoma elasticum and related PPi-deficiency calcification disorders. It highlights ABCC6 as the primary PXE gene and places ENPP1 and NT5E within the shared extracellular ATP-PPi-adenosine anti-mineralization pathway.

Causal Genes and Pathogenic Variants

The primary causal gene is ABCC6 (OMIM *603234), located on chromosome 16p13.11 (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). The gene encodes a 1503-amino acid transmembrane protein predominantly expressed in hepatocytes and renal tissues (verschuere2020frommembraneto pages 1-5, verschuere2020frommembraneto pages 8-10). More than 300–400 distinct pathogenic variants have been identified, including:

p.R1141X (recurrent nonsense mutation)
g.del23-29 (multiexon deletion)
Missense, frameshift, splice-site, and structural variants (li2019pseudoxanthomaelasticumas pages 1-6, marconi2015pseudoxanthomaelasticumand pages 1-2, plumers2023matrixmetalloproteinasescontribute pages 1-2, verschuere2020frommembraneto pages 8-10).

Variant Classification: Most ABCC6 variants are classified as pathogenic or likely pathogenic loss-of-function alleles per ACMG/AMP guidelines. Functional studies in HEK293 cells and patient fibroblasts support loss-of-function consequences (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Allele Frequency: PXE is rare, with estimated carrier frequency up to 1 in 80 for heterozygous ABCC6 mutations in the general population (germain2017pseudoxanthomaelasticum pages 2-4).

Germline vs Somatic: All reported PXE-causing ABCC6 variants are germline (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5).

Related Genes

ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1): Mutations cause classic GACI (Generalized Arterial Calcification of Infancy), and some ENPP1-deficient patients present PXE-like features (luo2020therapeuticsdevelopmentfor pages 1-3, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2).

NT5E (CD73): Mutations cause CALJA/ACDC (Calcification of Joints and Arteries / Arterial Calcification Due to CD73 Deficiency), part of the ectopic mineralization disease continuum (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2).

Modifier Genes

Rare modifier variants in genes involved in calcium homeostasis (e.g., TRPV1), vascular disease (e.g., SELE, CSF1R), and apoptosis (e.g., NLRP1) may collectively influence cardiovascular phenotype severity through IL-1B signaling pathways (vilder2021raremodifiervariants pages 1-2).

Epigenetic Information

Limited specific epigenetic data are available in retrieved PXE literature. Oxidative stress has been shown to inhibit ABCC6 gene expression in human cell lines, suggesting possible environmental or epigenetic modulation (germain2017pseudoxanthomaelasticum pages 4-5).

Chromosomal Abnormalities

The ABCC6 locus on 16p13.11 is prone to genomic rearrangements due to abundance of repetitive elements and flanking pseudogenes (ABCC6-Ψ1 and ABCC6-Ψ2) with ~99% sequence identity to the functional gene (verschuere2020frommembraneto pages 8-10).

5. Environmental Information

Environmental Factors

PXE is primarily a genetic disorder. However, oxidative stress from iron overload (as seen in β-thalassemia) can induce PXE-like syndrome, suggesting environmental oxidative damage may interact with genetic susceptibility (germain2017pseudoxanthomaelasticum pages 4-5).

Lifestyle Factors

Smoking, diet, and traditional cardiovascular risk factors (dyslipidemia, hypertension) may additively worsen vascular complications, although they do not directly cause PXE (stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2).

Infectious Agents

Not applicable; PXE is not caused by infectious agents.

6. Mechanism / Pathophysiology

Molecular Pathways

The central pathophysiological pathway in PXE is the ABCC6 → extracellular ATP → ENPP1 → PPi + AMP → CD73 → adenosine purinergic cascade (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, verschuere2020frommembraneto pages 8-10):

ABCC6 facilitates ATP efflux from hepatocytes into the extracellular space (kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 8-10).
ENPP1 hydrolyzes extracellular ATP to AMP and PPi (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).
CD73/NT5E converts AMP to adenosine (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).
PPi directly inhibits hydroxyapatite crystal nucleation and growth (shimada2021abcc6pyrophosphateand pages 1-2).
Adenosine indirectly inhibits calcification by suppressing tissue non-specific alkaline phosphatase (TNAP), which degrades PPi (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

ABCC6 deficiency reduces plasma PPi by approximately 60% in humans and mice, lowering the Pi/PPi ratio and permitting ectopic mineralization (leftheriotis2022relationshipsbetweenplasma pages 1-2, zedde2025abcc6involvementin pages 1-2, verschuere2020frommembraneto pages 8-10).

Cellular Processes

Elastic fiber fragmentation and calcification: Mid-dermal elastic fibers become short, fragmented, clumped, and progressively calcified (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Extracellular matrix (ECM) remodeling: PXE fibroblasts exhibit dysregulated ECM remodeling with elevated matrix metalloproteinases (MMPs), particularly MMP2, MMP9, and a cluster of MMPs on chromosome 11q21-23 (plumers2023matrixmetalloproteinasescontribute pages 1-2).
Oxidative stress: PXE patients show biochemical signs of oxidative stress, and oxidative damage may contribute to elastic fiber degeneration (germain2017pseudoxanthomaelasticum pages 4-5).
Cellular senescence: PXE fibroblasts display senescence-related features and altered lipid metabolism (plumers2023matrixmetalloproteinasescontribute pages 1-2).

GO Terms: GO:0030574 (collagen catabolic process), GO:0031012 (extracellular matrix), GO:0006874 (cellular calcium ion homeostasis), GO:0001503 (ossification).

Protein Dysfunction

ABCC6 loss-of-function mutations result in absent or severely reduced ATP efflux activity, impairing the upstream supply of substrate for PPi generation (kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 8-10). The exact transported substrate(s) remain uncertain, though ATP is strongly implicated (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Metabolic Changes

Reduced plasma PPi (approximately 40–60% of normal levels) (leftheriotis2022relationshipsbetweenplasma pages 1-2, verschuere2020frommembraneto pages 8-10).
Altered lipid metabolism: Metabolomic studies in ABCC6-deficient models show changes in fatty acids, glycerophospholipids, and cholesterol metabolism (verschuere2020frommembraneto pages 8-10).
Dysregulated nucleotide metabolism: Significant changes in nucleoside, nucleotide mono/di/triphosphate, and nucleotide sugar levels in ABCC6-transfected cells (verschuere2020frommembraneto pages 8-10).

Tissue Damage Mechanisms

Dystrophic calcification: Abnormal accumulation of calcium/phosphate complexes in elastic tissues with normal serum calcium and phosphate levels (germain2017pseudoxanthomaelasticum pages 1-2, li2019pseudoxanthomaelasticumas pages 1-6).
Elastic fiber degradation: MMPs make elastic fibers accessible to controlled, osteopontin-dependent calcium deposition (plumers2023matrixmetalloproteinasescontribute pages 1-2).
Vascular stiffness and occlusion: Arterial medial calcification leads to increased pulse wave velocity, peripheral artery disease, and stroke risk (stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2).

Biochemical Abnormalities

PPi deficiency is the central biochemical defect (shimada2021abcc6pyrophosphateand pages 1-2).
Reduced ENPP1 expression in peripheral tissues (dermal fibroblasts, liver) further compromises PPi production (plumers2023matrixmetalloproteinasescontribute pages 1-2).
Elevated osteopontin (OPN/SPP1): A mineralization-associated protein that may inhibit apatite crystal growth and colocalizes with calcification deposits (plumers2023matrixmetalloproteinasescontribute pages 1-2).

Molecular Profiling

Transcriptomics: RNA sequencing of PXE fibroblasts and Abcc6-/- mouse tissue reveals overexpression of MMPs (MMP2, MMP9, and an 11q21-23 cluster) and dysregulation of calcification-related genes (plumers2023matrixmetalloproteinasescontribute pages 1-2).

Proteomics: Secretome studies show that fibroblasts from calcified vs non-calcified skin areas differentially express pro- and anti-calcifying proteoglycans, glycoproteins, and elastic fiber-associated proteins (nollet2022serumcalcificationpropensity pages 1-2).

Metabolomics: Untargeted metabolomics in ABCC6-transfected cells and patient samples document alterations in purinergic metabolites, lipids, and mineralization-related small molecules (verschuere2020frommembraneto pages 8-10).

7. Anatomical Structures Affected

Organ Level

Primary Organs: - Skin: Mid-dermal elastic fibers in neck, flexural areas (axillae, inguinal, popliteal regions) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Eyes: Bruch's membrane in the retina (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Cardiovascular system: Small and medium-sized arteries, particularly lower extremity vessels, coronary arteries, and cerebral vasculature (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2).

Secondary Organs: - Kidneys, breasts, pancreas, testicles, liver, spleen: Calcification has been observed variably; clinical impact generally minor except kidneys (germain2017pseudoxanthomaelasticum pages 2-4). - Gastrointestinal tract: Vascular involvement leading to bleeding (germain2017pseudoxanthomaelasticum pages 2-4).

Body Systems: Integumentary, ocular, cardiovascular, nervous (secondary via cerebrovascular disease), gastrointestinal.

UBERON Terms: UBERON:0000014 (skin of body), UBERON:0010230 (Bruch's membrane), UBERON:0001637 (artery), UBERON:0000947 (aorta), UBERON:0001621 (coronary artery).

Tissue and Cell Level

Tissue Types: - Elastic connective tissue (mid-dermis, arterial media, Bruch's membrane) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Vascular smooth muscle within arterial walls (germain2017pseudoxanthomaelasticum pages 2-4).

Cell Populations: - Dermal fibroblasts: Show pro-calcification phenotype and altered ECM remodeling (plumers2023matrixmetalloproteinasescontribute pages 1-2). - Hepatocytes: Primary site of ABCC6 expression and ATP efflux; deficiency here drives systemic PPi depletion (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5). - Renal tubular cells: Secondary site of ABCC6 expression contributing to PPi homeostasis (verschuere2020frommembraneto pages 8-10).

Cell Ontology Terms: CL:0000057 (fibroblast), CL:0000182 (hepatocyte), CL:0000501 (epithelial cell of proximal tubule).

Subcellular Level

ABCC6 localizes to the basolateral plasma membrane of hepatocytes (germain2017pseudoxanthomaelasticum pages 4-5). Some reports suggest mitochondria-associated membrane localization in mice, but primary evidence supports plasma membrane function (germain2017pseudoxanthomaelasticum pages 4-5).

GO Cellular Component Terms: GO:0016323 (basolateral plasma membrane), GO:0005886 (plasma membrane).

8. Temporal Development

Onset

Typical age of onset: Second decade of life (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3); skin changes often first appear in childhood to adolescence (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Onset pattern: Insidious/chronic; rarely presents at birth, though rare neonatal or early childhood presentations occur (marconi2015pseudoxanthomaelasticumand pages 1-2).

Progression

Disease stages: Early (dermal papules, peau d'orange), intermediate (angioid streaks, arterial calcification), advanced (CNV, severe PAD, vision loss, stroke) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Progression rate: Slow, progressive over decades (germain2017pseudoxanthomaelasticum pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2); age is the major determinant of calcification severity (leftheriotis2022relationshipsbetweenplasma pages 1-2).
Disease course: Chronic, progressive; no spontaneous remission reported (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Duration: Lifelong chronic disease (germain2017pseudoxanthomaelasticum pages 1-2).

Patterns

Remission: Not applicable; no spontaneous or treatment-induced remission of underlying mineralization (germain2017pseudoxanthomaelasticum pages 1-2).
Critical periods: Visual complications may become severe in 40s if untreated; cardiovascular events increase with advancing age (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4).

9. Inheritance and Population

Epidemiology

Prevalence: Estimated at 1 per 25,000 to 1 per 100,000 in the general population (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2, marconi2015pseudoxanthomaelasticumand pages 1-2).
Incidence: Specific annual incidence data not provided in retrieved literature.
Sex ratio: Slight female predominance (approximately 2:1 female:male) (marconi2015pseudoxanthomaelasticumand pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2).

Inheritance Pattern

Mode of inheritance: Autosomal recessive (germain2017pseudoxanthomaelasticum pages 1-2, marconi2015pseudoxanthomaelasticumand pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5).
Penetrance: High for biallelic pathogenic variants, with age-dependent and variable expressivity (germain2017pseudoxanthomaelasticum pages 4-5, germain2017pseudoxanthomaelasticum pages 2-4).
Expressivity: Variable inter- and intra-familial phenotypic variability without clear genotype-phenotype correlations (marconi2015pseudoxanthomaelasticumand pages 1-2, vilder2021raremodifiervariants pages 1-2).
Genetic anticipation: Not reported in PXE.
Germline mosaicism: Not emphasized in retrieved literature.
Founder effects: Specific population founder mutations not detailed in retrieved contexts, though recurrent variants (p.R1141X, g.del23-29) suggest possible founder contributions.
Consanguinity: Increases risk as in any autosomal recessive disorder (marconi2015pseudoxanthomaelasticumand pages 1-2).
Carrier frequency: Up to 1 in 80 for heterozygous ABCC6 mutations (germain2017pseudoxanthomaelasticum pages 2-4).

Population Demographics

Affected populations: No strong ethnic predilection reported in retrieved literature; disease described in diverse populations (germain2017pseudoxanthomaelasticum pages 1-2, zedde2025abcc6involvementin pages 1-2).
Geographic distribution: Worldwide; no endemic regions identified (germain2017pseudoxanthomaelasticum pages 1-2).

10. Diagnostics

Clinical Tests

Laboratory Tests: - Plasma PPi measurement: Reduced levels (approximately 40–60% of normal) are characteristic but not routinely used diagnostically (leftheriotis2022relationshipsbetweenplasma pages 1-2, verschuere2020frommembraneto pages 8-10). - Serum calcification propensity (T50 test): Shorter T50 (indicative of higher calcification propensity) associated with more severe ocular, vascular, and overall disease; emerging as a potential biomarker (nollet2022serumcalcificationpropensity pages 1-2). - Serum fetuin-A, phosphorus, magnesium: Determinants of T50; may provide mechanistic insights (nollet2022serumcalcificationpropensity pages 1-2).

Biomarkers: - Plasma PPi: Low levels confirm PPi deficiency but show weak correlation with calcification severity and do not predict progression well (leftheriotis2022relationshipsbetweenplasma pages 1-2). - T50 serum calcification propensity: Inversely correlates with disease severity (nollet2022serumcalcificationpropensity pages 1-2). - Desmosine and isodesmosine: Biomarkers of elastin degradation (nollet2022serumcalcificationpropensity pages 1-2).

Imaging Studies: - Optical coherence tomography (OCT): Increased RPE-Bruch's membrane peak reflectivity in PXE patients (median 67.5 vs 32.7 in controls, p=2.43×10⁻⁵) with high discriminative value (AUC 0.85) for quantifying Bruch's membrane calcification (risseeuw2020areflectivitymeasure pages 1-2). - Fundus autofluorescence and near-infrared imaging: Identify peau d'orange and angioid streaks (risseeuw2020areflectivitymeasure pages 1-2). - Computed tomography (CT): Quantifies arterial calcification (coronary, lower limb) (kranenburg2018etidronateforprevention pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2). - 18F-NaF PET: Measures active arterial mineralization; used in clinical trials as a sensitive endpoint (kranenburg2018etidronateforprevention pages 1-2).

Functional Tests: - Ankle-brachial index (ABI): Abnormally low in PXE due to arterial wall remodeling, independently of traditional cardiovascular risk factors (germain2017pseudoxanthomaelasticum pages 2-4). - Pulmonary function testing: Some patients show reduced carbon monoxide diffusing capacity, suggesting preclinical interstitial lung involvement (germain2017pseudoxanthomaelasticum pages 2-4).

Pathology Findings: - Skin biopsy: Accumulation of pleomorphic elastotic material in mid-dermis visualized by Verhoeff-van Gieson or Orcein stains; calcification demonstrated by von Kossa or Alizarin red staining (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2). - Electron microscopy: Bulky, needle-like mineral deposits disrupting elastic fibers (germain2017pseudoxanthomaelasticum pages 1-2).

Genetic Testing

Recommended Approach: - Whole exome sequencing (WES) or targeted ABCC6 gene sequencing is the primary diagnostic approach when PXE is clinically suspected (germain2017pseudoxanthomaelasticum pages 1-2, verschuere2020frommembraneto pages 8-10). - Gene panels including ABCC6, ENPP1, and NT5E can capture the ectopic mineralization disease spectrum (shimada2021abcc6pyrophosphateand pages 1-2).

Single Gene Testing: - ABCC6 sequencing: Identifies pathogenic variants in >95% of clinically diagnosed PXE cases when both alleles are analyzed (marconi2015pseudoxanthomaelasticumand pages 1-2, verschuere2020frommembraneto pages 8-10). - Challenges: Presence of two ABCC6 pseudogenes (ABCC6-Ψ1, ABCC6-Ψ2) with ~99% sequence identity complicates sequencing and requires specialized strategies to distinguish functional gene from pseudogenes (verschuere2020frommembraneto pages 8-10).

Chromosomal Microarray and Structural Variant Detection: - MLPA (multiplex ligation-dependent probe amplification) or array CGH can detect multiexon deletions such as g.del23-29 (verschuere2020frommembraneto pages 8-10).

Clinical Criteria

Diagnostic Criteria (Plomp et al., revised): Diagnosis based on combination of: 1. Characteristic skin findings with histopathology showing mid-dermal elastic fiber calcification. 2. Ocular findings (angioid streaks, peau d'orange). 3. Family history and/or demonstration of biallelic pathogenic ABCC6 variants (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2).

Differential Diagnosis: - PXE-like disorders: β-thalassemia-associated PXE-like syndrome (acquired, oxidative stress-mediated, without ABCC6 mutations) (germain2017pseudoxanthomaelasticum pages 4-5). - GACI (ENPP1 or ABCC6 mutations): More severe, early-onset arterial calcification (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2). - CALJA/ACDC (NT5E mutations): Late-onset juxta-articular and arterial calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2). - Cutis laxa: Lax skin without characteristic calcification (germain2017pseudoxanthomaelasticum pages 1-2). - Other causes of angioid streaks: Sickle cell disease, thalassemia, Ehlers-Danlos syndrome (germain2017pseudoxanthomaelasticum pages 2-4).

Screening

Cascade screening: Genetic testing of at-risk family members (siblings, offspring of affected individuals) is recommended for early diagnosis and surveillance (germain2017pseudoxanthomaelasticum pages 1-2).
Newborn screening: Not currently standard for PXE.

11. Outcome/Prognosis

Survival and Mortality

Life expectancy: Generally near-normal lifespan for many patients, though cardiovascular complications can reduce life expectancy in some cases (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Mortality rate: Cardiac complications (myocardial infarction, angina) and strokes are occasional causes of premature mortality, but are thought to be relatively rare (germain2017pseudoxanthomaelasticum pages 2-4).
Disease-specific mortality: Not quantitatively specified in retrieved contexts; cardiovascular events and gastrointestinal bleeding are potential life-threatening complications (germain2017pseudoxanthomaelasticum pages 2-4).

Morbidity and Function

Morbidity: High due to visual impairment, peripheral artery disease, intermittent claudication, and stroke risk (germain2017pseudoxanthomaelasticum pages 2-4, stumpf2021therapyofpseudoxanthoma pages 1-2).
Disability outcomes: Severe visual impairment and blindness can occur by the 40s without treatment; mobility limitations from PAD (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4).
Quality of life: Visual impairment causes major degradation in vision-related QoL; vascular disease contributes to reduced social/occupational participation; cardiovascular complications show relatively less impact on general health-related QoL measures than visual complications (germain2017pseudoxanthomaelasticum pages 2-4).

Disease Course and Complications

Complications: Choroidal neovascularization with bleeding/scarring, central vision loss, peripheral artery disease, intermittent claudication, ischemic stroke, gastrointestinal bleeding, potential for myocardial infarction (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Recovery potential: No spontaneous recovery; anti-VEGF therapy can stabilize or improve vision if CNV is detected early (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3).

Prognostic Factors

Age: Major determinant of calcification severity; older age correlates with more extensive arterial calcification and ocular disease (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4).
Sex: Females may have higher plasma PPi levels and lower lower-limb arterial calcification than males, suggesting sex-related modulation (leftheriotis2022relationshipsbetweenplasma pages 1-2).
Serum T50: Shorter T50 (higher calcification propensity) independently predicts more severe ocular, vascular, and overall disease severity (nollet2022serumcalcificationpropensity pages 1-2).

12. Treatment

Treatment Category	Specific Treatment/Intervention	Mechanism of Action	Evidence Level	Outcome/Efficacy	Side Effects/Safety	Status	MAXO terms (suggested)
Ophthalmologic pharmacotherapy	Intravitreal anti-VEGF therapy (e.g., ranibizumab, bevacizumab, aflibercept class)	Inhibits VEGF-driven choroidal neovascularization secondary to breaks/calcification in Bruch’s membrane	Established clinical practice; supported by review-level clinical evidence (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2)	Main symptomatic treatment for ophthalmic PXE; can prevent progression to hemorrhage/scarring and preserve central vision when CNV is treated promptly (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	Standard intravitreal injection risks not detailed in retrieved contexts; no PXE-specific major safety signal highlighted in retrieved sources (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	Standard-of-care symptomatic treatment; not disease-curative (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)	MAXO: anti-VEGF therapy; intravitreal injection; treatment of choroidal neovascularization
Anti-mineralization pharmacotherapy	Etidronate (cyclical oral bisphosphonate)	Stable pyrophosphate analog; inhibits hydroxyapatite crystal growth and ectopic mineralization	Randomized placebo-controlled clinical trial in PXE (n=74) (kranenburg2018etidronateforprevention pages 1-2)	Over 12 months, arterial calcification decreased 4% (IQR -11% to 7%) with etidronate versus increased 8% (IQR -1% to 20%) with placebo (p=0.001); fewer subretinal neovascularization events (1 vs 9; p=0.007) (kranenburg2018etidronateforprevention pages 1-2)	No major safety issues in trial; hyperphosphatemia in 48.6% vs 0% placebo, recovered spontaneously; hypocalcemia infrequent; bone density change not significantly different (kranenburg2018etidronateforprevention pages 1-2)	Investigational / off-label disease-modifying candidate; not specifically approved for PXE (kranenburg2018etidronateforprevention pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	MAXO: bisphosphonate therapy; ectopic calcification prevention; oral drug administration
Anti-mineralization pharmacotherapy	Bisphosphonates (class concept beyond etidronate)	PPi analogs that inhibit calcium phosphate crystal formation/deposition	Preclinical + review evidence; class discussed as therapeutic strategy (plumers2023matrixmetalloproteinasescontribute pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Considered promising because PXE is a PPi-deficiency disorder; strongest direct human evidence among class is etidronate trial (kranenburg2018etidronateforprevention pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Class-related safety issues not detailed in retrieved PXE contexts beyond etidronate findings (kranenburg2018etidronateforprevention pages 1-2)	Investigational / off-label in PXE (shimada2021abcc6pyrophosphateand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	MAXO: bisphosphonate therapy
Enzyme replacement / pathway restoration	INZ-701 (recombinant ENPP1)	Restores extracellular ENPP1 activity, raising plasma PPi by using circulating ATP substrate	Preclinical mouse study in Abcc6-/- PXE model (jacobs2022inz‐701arecombinant pages 1-3)	Increased steady-state plasma ENPP1 activity and PPi; significantly reduced ectopic calcification in muzzle skin biomarker tissue after 8 weeks (jacobs2022inz‐701arecombinant pages 1-3)	Human safety not available in retrieved PXE contexts; preclinical study supports therapeutic potential (jacobs2022inz‐701arecombinant pages 1-3)	Preclinical / investigational for PXE (jacobs2022inz‐701arecombinant pages 1-3)	MAXO: enzyme replacement therapy; recombinant protein therapy; pyrophosphate restoration
Nutritional / metabolic support	Magnesium supplementation / increased magnesium	May reduce calcification propensity by influencing mineral buffering and crystal formation; magnesium associated with higher T50 (calcification resistance) (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Biomarker association + review/preclinical rationale (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Not proven as definitive therapy in retrieved human PXE trials; biologically plausible adjunct because magnesium was a determinant of serum T50 (p=0.034) (nollet2022serumcalcificationpropensity pages 1-2)	Specific PXE safety data not detailed in retrieved contexts (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Supportive / investigational adjunct (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	MAXO: magnesium supplementation; dietary mineral supplementation
Lifestyle / risk reduction	Lifestyle modification and vascular risk-factor control	Reduces additive cardiovascular risk in a disease with arterial calcification/PAD and stroke risk	Review/guideline-style clinical recommendation (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2)	Recommended as part of standard management; aimed at reducing vascular complications rather than reversing PXE (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Generally safe; details not quantified in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Standard supportive care (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	MAXO: lifestyle modification; cardiovascular risk reduction; smoking avoidance; exercise counseling
Lipid-lowering / vascular prevention	Lipid-lowering measures	Addresses cardiovascular risk burden and possible dyslipidemia contribution	Review-level clinical recommendation (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2)	Used to reduce vascular risk factors; not shown in retrieved contexts to reverse mineralization directly (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Drug-specific adverse effects not detailed in retrieved PXE contexts (germain2017pseudoxanthomaelasticum pages 1-2)	Supportive standard care when indicated (germain2017pseudoxanthomaelasticum pages 1-2)	MAXO: lipid-lowering therapy
Surgical / interventional vascular care	Vascular surgery / endovascular intervention for severe PAD or arterial lesions	Revascularization or treatment of advanced vascular stenosis/occlusion	Clinical practice / symptomatic management (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Reserved for severe cardiovascular manifestations; may be necessary in advanced stages of PAD (germain2017pseudoxanthomaelasticum pages 1-2, vilder2021raremodifiervariants pages 1-2)	Success may be affected by distal vessel involvement/calcification; careful vascular assessment recommended (germain2017pseudoxanthomaelasticum pages 2-4)	Standard symptomatic intervention when indicated (germain2017pseudoxanthomaelasticum pages 1-2)	MAXO: vascular surgery; endovascular procedure; peripheral revascularization
Dermatologic / cosmetic management	Management of skin lesions / cosmetic care	Addresses lax redundant skin and cosmetic burden rather than underlying metabolic defect	Review-level clinical experience (marconi2015pseudoxanthomaelasticumand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Cutaneous findings are primarily cosmetic concern; treatment does not address systemic disease (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2)	Safety depends on procedure; specific PXE data limited in retrieved contexts (marconi2015pseudoxanthomaelasticumand pages 1-2)	Supportive / symptomatic (marconi2015pseudoxanthomaelasticumand pages 1-2)	MAXO: dermatologic care; cosmetic intervention
Experimental small-molecule therapy	Minocycline	DDR/PARP1-modulating effects; proposed anticalcifying activity in PXE pathogenesis	Preclinical proof-of-concept in Abcc6-/- mice (jacobs2022inz‐701arecombinant pages 1-3)	Oral minocycline reduced ectopic calcification by 43.4% (p<0.0001) in Abcc6-/- mice; supported by H2AX evidence of DDR activation at calcification sites (jacobs2022inz‐701arecombinant pages 1-3)	Favorable human safety profile noted generally in paper abstract, but no PXE clinical safety data provided (jacobs2022inz‐701arecombinant pages 1-3)	Preclinical / investigational repurposing candidate (jacobs2022inz‐701arecombinant pages 1-3)	MAXO: tetracycline therapy; DNA-damage-response modulation
Experimental anti-crystallization therapy	SNF472 / CSL525 (hexasodium fytate)	Direct inhibitor of calcium phosphate crystallization	Preclinical animal studies (zebrafish, mouse, rat models) (kranenburg2018etidronateforprevention pages 1-2)	Reduced calcified area by ~40% in abcc6a-/- zebrafish larvae; inhibited muzzle calcification by 57% in abcc6-/- mice; inhibited rat skin calcification by 60% (kranenburg2018etidronateforprevention pages 1-2)	Human PXE safety not available in retrieved contexts (kranenburg2018etidronateforprevention pages 1-2)	Preclinical / investigational (kranenburg2018etidronateforprevention pages 1-2)	MAXO: calcification inhibitor therapy; phytate therapy
Gene-based therapy	Gene therapy / gene editing / liver-directed correction of ABCC6	Restores ABCC6 function in liver, the main source of systemic anti-calcification signaling	Review/future perspective in PXE; preclinical direction supported broadly (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	Considered a plausible future disease-modifying approach; no approved human PXE gene therapy in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Clinical safety not established for PXE in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2)	Investigational / conceptual-preclinical (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	MAXO: gene therapy; genome editing; liver-directed gene transfer
Pharmacologic chaperone strategy	Pharmacologic chaperone therapy for selected ABCC6 variants	Aims to rescue trafficking/function of misfolded but potentially rescuable ABCC6 protein	Review/future perspective (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2)	Potentially useful for certain variant classes; no established clinical efficacy in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2)	Safety unknown in PXE clinical practice from retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2)	Investigational / conceptual-preclinical (germain2017pseudoxanthomaelasticum pages 1-2)	MAXO: pharmacologic chaperone therapy
Supportive care / monitoring	Regular ophthalmologic, dermatologic, and vascular surveillance	Early detection and management of CNV, PAD, calcification progression, and complications	Standard clinical management supported by natural history/diagnostic literature (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2)	Important because progression is chronic and age-dependent; enables timely anti-VEGF and vascular intervention (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2)	Low procedural risk from surveillance itself; burden of repeated monitoring not quantified (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2)	Standard supportive care (germain2017pseudoxanthomaelasticum pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2)	MAXO: clinical surveillance; ophthalmologic monitoring; vascular monitoring
Biomarker-guided trial support	OCT Bruch’s membrane reflectivity; serum T50 as trial/monitoring biomarkers	Imaging/serum endpoints to quantify retinal calcification and systemic calcification propensity	Observational biomarker studies (risseeuw2020areflectivitymeasure pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	OCT RPE-BM peak reflectivity discriminated PXE from controls with AUC 0.85; shorter T50 associated with more severe ocular, vascular, and overall disease (risseeuw2020areflectivitymeasure pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	Biomarkers themselves are low-risk; clinical utility for routine treatment decisions still emerging (nollet2022serumcalcificationpropensity pages 1-2, risseeuw2020areflectivitymeasure pages 1-2)	Investigational as outcome measures / companion tools (nollet2022serumcalcificationpropensity pages 1-2, risseeuw2020areflectivitymeasure pages 1-2)	MAXO: biomarker monitoring; optical coherence tomography; serum assay monitoring

Table: This table summarizes current, investigational, and preclinical treatment strategies for pseudoxanthoma elasticum, including mechanisms, evidence strength, outcomes, safety considerations, and suggested MAXO mappings. It is useful for quickly comparing symptomatic care versus emerging disease-modifying approaches.

Pharmacotherapy

Ophthalmologic: - Anti-VEGF therapy (ranibizumab, bevacizumab, aflibercept): Standard of care for choroidal neovascularization; prevents progression to hemorrhage and vision loss (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2).

Anti-Mineralization: - Etidronate (bisphosphonate): A randomized placebo-controlled trial (n=74) showed reduced arterial calcification (−4% vs +8% placebo, p=0.001) and fewer subretinal neovascularization events (1 vs 9, p=0.007) over 12 months, without major safety issues (kranenburg2018etidronateforprevention pages 1-2).

Investigational Enzyme Replacement: - INZ-701 (recombinant ENPP1): Preclinical study in Abcc6-/- mice showed increased plasma PPi and significantly reduced muzzle skin calcification after 8 weeks (jacobs2022inz‐701arecombinant pages 1-3).

Advanced Therapeutics

Gene Therapy: - Liver-directed ABCC6 gene therapy/editing: Conceptual future approach; no approved clinical trials in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2).

Experimental Small Molecules: - Minocycline: Reduced ectopic calcification by 43.4% (p<0.0001) in Abcc6-/- mice via DNA-damage-response modulation; favorable safety profile suggests repurposing potential (jacobs2022inz‐701arecombinant pages 1-3). - SNF472/CSL525 (hexasodium fytate): Direct calcification inhibitor reduced calcification by 40–60% in zebrafish, mouse, and rat models (kranenburg2018etidronateforprevention pages 1-2).

Supportive and Rehabilitative Care

Lifestyle modification and cardiovascular risk reduction: Recommended to mitigate additional vascular risk (smoking cessation, lipid control, blood pressure management) (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2).
Vascular surgery: Reserved for severe PAD; success may be affected by distal vessel calcification (germain2017pseudoxanthomaelasticum pages 1-2, vilder2021raremodifiervariants pages 1-2).
Regular ophthalmologic, vascular, and dermatologic surveillance: Enables early detection and treatment of CNV and PAD (germain2017pseudoxanthomaelasticum pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2).

Treatment Outcomes

Etidronate trial: Reduced arterial calcification and CNV events; hyperphosphatemia was common but self-limited (kranenburg2018etidronateforprevention pages 1-2).
Anti-VEGF: Standard symptomatic treatment preserving vision when CNV is treated promptly (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3).

MAXO Terms

Suggested MAXO terms are included in artifact-02 for each treatment category.

13. Prevention

Prevention Levels

Primary Prevention: - Not applicable for this genetic disorder; genetic counseling and carrier screening in at-risk families can guide reproductive decisions (germain2017pseudoxanthomaelasticum pages 1-2).

Secondary Prevention: - Early detection via cascade screening of at-risk family members enables earlier surveillance and intervention (germain2017pseudoxanthomaelasticum pages 1-2). - Regular ophthalmologic surveillance to detect CNV early and initiate anti-VEGF therapy (germain2017pseudoxanthomaelasticum pages 1-2, risseeuw2020areflectivitymeasure pages 1-2).

Tertiary Prevention: - Management of cardiovascular risk factors (lifestyle, lipid-lowering, antihypertensives) to reduce additive vascular complications (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2). - Anti-VEGF therapy for CNV to prevent blindness (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3).

Genetic Screening and Counseling

Carrier screening: Heterozygous carriers identified in families can inform genetic counseling and reproductive planning (germain2017pseudoxanthomaelasticum pages 1-2).
Genetic counseling: Risk assessment and family planning guidance for affected individuals and carrier families (germain2017pseudoxanthomaelasticum pages 1-2, vilder2021raremodifiervariants pages 1-2).

Behavioral Interventions

Smoking cessation, healthy diet, regular exercise: Reduce cardiovascular risk burden (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2).

14. Other Species / Natural Disease

Limited information on naturally occurring PXE in other species was retrieved. PXE is primarily a human genetic disorder. However, animal models (discussed below) are critical for research.

15. Model Organisms

Model Type	Species/Model Name	Genetic Background	Phenotype Recapitulation	Research Applications	Model Advantages	Model Limitations	Key Resources/References
Mammalian knockout model	Abcc6-/- mouse	Targeted deletion of Abcc6; widely used knockout line, including congenic strains; earliest calcification readout is the connective tissue sheath of vibrissae/muzzle skin (jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10)	Recapitulates ectopic calcification in skin, vasculature, ocular tissues, and kidneys; mineralization of vibrissae capsule is a robust biomarker; mirrors PPi deficiency and progressive soft-tissue mineralization seen in human PXE (leftheriotis2022relationshipsbetweenplasma pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10)	Pathomechanism studies of PPi deficiency, testing anti-calcification therapies (etidronate, INZ-701, minocycline), biomarker development, natural-history studies, and tissue-level histopathology (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2)	Best-established mammalian PXE model; strong face validity for systemic calcification; supports longitudinal intervention studies and quantitative histology/biochemistry (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)	Does not fully capture all human chronic ocular/vascular outcomes; vibrissae calcification is a convenient biomarker but not a direct human anatomical correlate; murine disease course differs from human timing/severity (leftheriotis2022relationshipsbetweenplasma pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)	INZ-701 prevention study; minocycline proof-of-concept; general PXE pathway reviews (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, li2019pseudoxanthomaelasticumas pages 1-6)
Mammalian rat model	Abcc6-/- rat	Rat knockout for Abcc6; cited as sharing many commonalities with human ABCC6 deficiency (verschuere2020frommembraneto pages 8-10)	Shows ectopic mineralization of blood vessels, Bruch's membrane, and skin, with hallmark vibrissae sheath mineralization similar to mouse; also shows reduced plasma PPi and kidney PPi excretion data (verschuere2020frommembraneto pages 8-10)	Comparative mammalian physiology, systemic PPi biology, ocular histology, and validation of liver-kidney contributions to mineralization homeostasis (verschuere2020frommembraneto pages 8-10)	Larger size may benefit imaging, tissue sampling, and some physiology studies; closer procedural flexibility than mouse for some assays (verschuere2020frommembraneto pages 8-10)	Much less extensively characterized than the mouse in retrieved PXE literature; fewer intervention datasets and fewer standardized community resources noted here (verschuere2020frommembraneto pages 8-10)	ABCC6 cross-species review and comparative biology discussion (verschuere2020frommembraneto pages 8-10)
Zebrafish genetic model	abcc6a-/- zebrafish	Loss of abcc6a, regarded as the most likely zebrafish ortholog of human ABCC6; abcc6a expressed locally by osteoblast-like cells at craniofacial and skeletal mineralization sites (verschuere2020frommembraneto pages 8-10)	Recapitulates aberrant mineralization, though with a more skeletal/local developmental pattern than classic human hepatic-systemic PXE; used as calcification-readout model for anti-mineralization compounds (jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10)	Rapid in vivo screening of anti-calcification compounds such as minocycline and SNF472/CSL525; developmental mineralization studies; pathway probing (jacobs2022inz‐701arecombinant pages 1-3, kranenburg2018etidronateforprevention pages 1-2, verschuere2020frommembraneto pages 8-10)	Fast, scalable, transparent vertebrate model suitable for higher-throughput drug screening and early mechanism studies (jacobs2022inz‐701arecombinant pages 1-3, kranenburg2018etidronateforprevention pages 1-2)	Mineralization pattern is not fully homologous to human PXE because zebrafish abcc6a acts more locally in skeletal mineralization than mammalian liver-driven systemic PXE; limited direct translation for skin/eye phenotypes (verschuere2020frommembraneto pages 8-10)	Comparative ABCC6 review; drug-testing studies using zebrafish mineralization endpoints (verschuere2020frommembraneto pages 8-10, kranenburg2018etidronateforprevention pages 1-2, jacobs2022inz‐701arecombinant pages 1-3)
Zebrafish paralog model / comparative system	abcc6b(1/2) zebrafish	Zebrafish paralogs abcc6b1/abcc6b2; abcc6b expressed in renal proximal tubules, with function less clearly defined (verschuere2020frommembraneto pages 8-10)	No fully defined PXE-like phenotype summarized in retrieved contexts; mainly relevant as a comparative paralog system for understanding tissue-specific ABCC6 evolution and function (verschuere2020frommembraneto pages 8-10)	Comparative genomics, functional dissection of paralog specialization, and kidney-related ABCC6 biology (verschuere2020frommembraneto pages 8-10)	Useful for evolutionary and orthology questions that cannot be addressed in mammalian single-gene systems (verschuere2020frommembraneto pages 8-10)	Unclear disease validity for human PXE; limited direct phenotypic application in retrieved studies (verschuere2020frommembraneto pages 8-10)	ABCC6 phylogenetics and zebrafish paralog discussion (verschuere2020frommembraneto pages 8-10)
Primary cellular model	PXE patient dermal fibroblasts	Fibroblasts isolated from lesional or non-lesional skin of individuals with biallelic ABCC6 pathogenic variants; often compared with control dermal fibroblasts (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	Show pro-calcification phenotype, lower cytosolic/extracellular PPi, lower ENPP1 expression, altered ECM remodeling, elevated MMPs, altered lipid metabolism/senescence-related features, and skin microenvironment differences between calcified and non-calcified areas (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	ECM remodeling studies, secretome analysis, MMP biology, calcification induction assays, biomarker discovery, testing inhibitors such as Marimastat and mechanistic work on local dermal drivers of mineralization (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	Human patient-derived system captures cell-autonomous and microenvironmental features of PXE skin; useful for mechanistic and translational in vitro assays (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2)	Peripheral fibroblasts express much lower ABCC6 than liver, so they do not model the full systemic liver-driven component of PXE; culture artifacts and inter-patient variability can be substantial (germain2017pseudoxanthomaelasticum pages 4-5, plumers2023matrixmetalloproteinasescontribute pages 1-2)	MMP overexpression study; fibroblast secretome study; older pathophysiology review (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5)
Engineered cell system	HEK293 cells expressing human or rat ABCC6	Heterologous overexpression of hABCC6 or rABCC6 in HEK293 cells for transport/metabolomic studies (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5)	Does not model tissue calcification directly; demonstrates ABCC6-associated extracellular nucleotide changes and supports the link between ABCC6 activity, ATP-related efflux, and PPi biology (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5)	Transport assays, substrate discovery, untargeted metabolomics, mechanistic analysis of ATP/PPi-related signaling, and variant-function interrogation (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5)	Highly manipulable system for biochemical and transport-focused studies; useful for dissecting upstream molecular function of ABCC6 (verschuere2020frommembraneto pages 8-10)	Low physiological context; no connective tissue matrix or whole-organism mineralization phenotype; substrate identity remains unresolved despite these systems (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5)	ABCC6 transport/function reviews and mechanistic summaries (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5, kauffenstein2024thepurinergicnature pages 1-2)

Table: This table summarizes the main in vivo and in vitro model systems used in pseudoxanthoma elasticum research, including what parts of the human disease they capture and where they are most useful. It helps compare mammalian, zebrafish, and cellular platforms for mechanism, biomarker, and therapeutic studies.

Key Model Systems

Abcc6-/- mouse: Most established mammalian model; recapitulates systemic calcification with vibrissae sheath mineralization as a robust biomarker; widely used for therapeutic testing (INZ-701, etidronate, minocycline) (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2).

Abcc6-/- rat: Shares many features with mouse; provides kidney PPi excretion data and comparative mammalian physiology (verschuere2020frommembraneto pages 8-10).

abcc6a-/- zebrafish: Rapid, scalable model for screening anti-calcification compounds; skeletal/local mineralization pattern differs from hepatic-systemic human PXE (verschuere2020frommembraneto pages 8-10, kranenburg2018etidronateforprevention pages 1-2, jacobs2022inz‐701arecombinant pages 1-3).

PXE patient fibroblasts: Human-derived system for studying ECM remodeling, MMPs, secretome, and calcification induction; captures cell-autonomous and microenvironmental features (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2).

HEK293-hABCC6: Heterologous expression system for transport assays, substrate discovery, and metabolomics; does not model tissue calcification (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Conclusion

Pseudoxanthoma elasticum is a well-characterized genetic metabolic disorder caused by biallelic ABCC6 mutations leading to systemic PPi deficiency and progressive ectopic calcification in skin, eyes, and cardiovascular tissues. Recent advances include identification of the ABCC6-ENPP1-CD73 purinergic pathway, development of biomarkers (serum T50, OCT Bruch's membrane reflectivity), and emerging therapies such as etidronate, INZ-701, and minocycline. Comprehensive surveillance and early anti-VEGF treatment remain the mainstay of clinical management, with promising disease-modifying therapies in preclinical and early clinical development.

References

All cited information is supported by the context IDs provided throughout this report, corresponding to peer-reviewed publications from 2015–2025.

References

(stumpf2021therapyofpseudoxanthoma pages 1-2): Max Jonathan Stumpf, Nadjib Schahab, Georg Nickenig, Dirk Skowasch, and Christian Alexander Schaefer. Therapy of pseudoxanthoma elasticum: current knowledge and future perspectives. Biomedicines, 9:1895, Dec 2021. URL: https://doi.org/10.3390/biomedicines9121895, doi:10.3390/biomedicines9121895. This article has 39 citations.
(germain2017pseudoxanthomaelasticum pages 1-2): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.
(luo2020therapeuticsdevelopmentfor pages 1-3): Hongbin Luo, Qiaoli Li, Yi Cao, and Jouni Uitto. Therapeutics development for pseudoxanthoma elasticum and related ectopic mineralization disorders: update 2020. Journal of Clinical Medicine, 10:114, Dec 2020. URL: https://doi.org/10.3390/jcm10010114, doi:10.3390/jcm10010114. This article has 44 citations.
(kauffenstein2024thepurinergicnature pages 1-2): Gilles Kauffenstein, Ludovic Martin, and Olivier Le Saux. The purinergic nature of pseudoxanthoma elasticum. Biology, Jan 2024. URL: https://doi.org/10.3390/biology13020074, doi:10.3390/biology13020074. This article has 9 citations.
(marconi2015pseudoxanthomaelasticumand pages 1-2): Barbara Marconi, Ivan Bobyr, Anna Campanati, Elisa Molinelli, Veronica Consales, Valerio Brisigotti, Marina Scarpelli, Stefano Racchini, and Annamaria Offidani. Pseudoxanthoma elasticum and skin: clinical manifestations, histopathology, pathomechanism, perspectives of treatment. Intractable & rare diseases research, 4 3:113-22, Jul 2015. URL: https://doi.org/10.5582/irdr.2015.01014, doi:10.5582/irdr.2015.01014. This article has 161 citations.
(kranenburg2018etidronateforprevention pages 1-2): Guido Kranenburg, Pim A. de Jong, Jonas W. Bartstra, Suzanne J. Lagerweij, Marnix G. Lam, Jeannette Ossewaarde-van Norel, Sara Risseeuw, Redmer van Leeuwen, Saskia M. Imhof, Harald J. Verhaar, Job J. de Vries, Riemer H.J.A. Slart, Gert Luurtsema, Annemarie M. den Harder, Frank L.J. Visseren, Willem P. Mali, and Wilko Spiering. Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum. Journal of the American College of Cardiology, 71 10:1117-1126, Mar 2018. URL: https://doi.org/10.1016/j.jacc.2017.12.062, doi:10.1016/j.jacc.2017.12.062. This article has 140 citations and is from a highest quality peer-reviewed journal.
(germain2017pseudoxanthomaelasticum pages 4-5): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.
(verschuere2020frommembraneto pages 1-5): Shana Verschuere, Matthias Van Gils, Lukas Nollet, and Olivier M. Vanakker. From membrane to mineralization: the curious case of the abcc6 transporter. FEBS Letters, 594:4109-4133, Nov 2020. URL: https://doi.org/10.1002/1873-3468.13981, doi:10.1002/1873-3468.13981. This article has 21 citations and is from a peer-reviewed journal.
(shimada2021abcc6pyrophosphateand pages 1-2): Briana K. Shimada, Viola Pomozi, Janna Zoll, Sheree Kuo, Ludovic Martin, and Olivier Le Saux. Abcc6, pyrophosphate and ectopic calcification: therapeutic solutions. International Journal of Molecular Sciences, 22:4555, Apr 2021. URL: https://doi.org/10.3390/ijms22094555, doi:10.3390/ijms22094555. This article has 64 citations.
(leftheriotis2022relationshipsbetweenplasma pages 1-2): Georges Leftheriotis, Nastassia Navasiolava, Laetitia Clotaire, Christophe Duranton, Olivier Le Saux, Saïd Bendahhou, Audrey Laurain, Isabelle Rubera, and Ludovic Martin. Relationships between plasma pyrophosphate, vascular calcification and clinical severity in patients affected by pseudoxanthoma elasticum. Journal of Clinical Medicine, 11:2588, May 2022. URL: https://doi.org/10.3390/jcm11092588, doi:10.3390/jcm11092588. This article has 28 citations.
(zedde2025abcc6involvementin pages 1-2): Marialuisa Zedde and Rosario Pascarella. Abcc6 involvement in cerebral small vessel disease: potential mechanisms and associations. Genes, 16:728, Jun 2025. URL: https://doi.org/10.3390/genes16070728, doi:10.3390/genes16070728. This article has 4 citations.
(verschuere2020frommembraneto pages 8-10): Shana Verschuere, Matthias Van Gils, Lukas Nollet, and Olivier M. Vanakker. From membrane to mineralization: the curious case of the abcc6 transporter. FEBS Letters, 594:4109-4133, Nov 2020. URL: https://doi.org/10.1002/1873-3468.13981, doi:10.1002/1873-3468.13981. This article has 21 citations and is from a peer-reviewed journal.
(li2019pseudoxanthomaelasticumas pages 1-6): Qiaoli Li, Koen van de Wetering, and Jouni Uitto. Pseudoxanthoma elasticum as a paradigm of heritable ectopic mineralization disorders: pathomechanisms and treatment development. The American journal of pathology, 189 2:216-225, Feb 2019. URL: https://doi.org/10.1016/j.ajpath.2018.09.014, doi:10.1016/j.ajpath.2018.09.014. This article has 79 citations.
(plumers2023matrixmetalloproteinasescontribute pages 1-2): Ricarda Plümers, Christopher Lindenkamp, Michel Robin Osterhage, Cornelius Knabbe, and Doris Hendig. Matrix metalloproteinases contribute to the calcification phenotype in pseudoxanthoma elasticum. Biomolecules, 13:672, Apr 2023. URL: https://doi.org/10.3390/biom13040672, doi:10.3390/biom13040672. This article has 10 citations.
(vilder2021raremodifiervariants pages 1-2): Eva Y. G. De Vilder, Ludovic Martin, Georges Lefthériotis, Paul Coucke, Filip Van Nieuwerburgh, and Olivier M. Vanakker. Rare modifier variants alter the severity of cardiovascular disease in pseudoxanthoma elasticum: identification of novel candidate modifier genes and disease pathways through mixture of effects analysis. Frontiers in Cell and Developmental Biology, Jun 2021. URL: https://doi.org/10.3389/fcell.2021.612581, doi:10.3389/fcell.2021.612581. This article has 14 citations.
(germain2017pseudoxanthomaelasticum pages 2-4): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.
(nollet2022serumcalcificationpropensity pages 1-2): Lukas Nollet, Matthias Van Gils, Suzanne Fischer, Laurence Campens, Swapna Karthik, Andreas Pasch, Julie De Zaeytijd, Bart P. Leroy, Daniel Devos, Tine De Backer, Paul J. Coucke, and Olivier M. Vanakker. Serum calcification propensity t50 associates with disease severity in patients with pseudoxanthoma elasticum. Journal of Clinical Medicine, 11:3727, Jun 2022. URL: https://doi.org/10.3390/jcm11133727, doi:10.3390/jcm11133727. This article has 11 citations.
(risseeuw2020areflectivitymeasure pages 1-2): Sara Risseeuw, Edwin Bennink, Maarten G. Poirot, Pim A. de Jong, Wilko Spiering, Saskia M. Imhof, Redmer van Leeuwen, and Jeannette Ossewaarde-van Norel. A reflectivity measure to quantify bruch's membrane calcification in patients with pseudoxanthoma elasticum using optical coherence tomography. Jul 2020. URL: https://doi.org/10.1167/tvst.9.8.34, doi:10.1167/tvst.9.8.34. This article has 17 citations and is from a peer-reviewed journal.
(jacobs2022inz‐701arecombinant pages 1-3): Ida Joely Jacobs, Zhiliang Cheng, Douglas Ralph, Kevin O'Brien, Lisa Flaman, Jennifer Howe, David Thompson, Jouni Uitto, Qiaoli Li, and Yves Sabbagh. inz‐701, a recombinant enpp1 enzyme, prevents ectopic calcification in an abcc6^−/− mouse model of pseudoxanthoma elasticum. Experimental Dermatology, 31:1095-1101, May 2022. URL: https://doi.org/10.1111/exd.14587, doi:10.1111/exd.14587. This article has 21 citations and is from a domain leading peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

Disease Definition and Overview

Key Identifiers

Data Source Classification

2. Etiology

Disease Causal Factors

Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Cutaneous Manifestations

Ophthalmological Manifestations

Cardiovascular and Vascular Manifestations

Gastrointestinal Manifestations

Quality of Life Impact

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

Related Genes

Modifier Genes

Epigenetic Information

Chromosomal Abnormalities

5. Environmental Information

Environmental Factors

Lifestyle Factors

Infectious Agents

6. Mechanism / Pathophysiology

Molecular Pathways

Cellular Processes

Protein Dysfunction

Metabolic Changes

Tissue Damage Mechanisms

Biochemical Abnormalities

Molecular Profiling

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern

Population Demographics

10. Diagnostics

Clinical Tests

Genetic Testing

Clinical Criteria

Screening

11. Outcome/Prognosis

Survival and Mortality

Morbidity and Function

Disease Course and Complications

Prognostic Factors

12. Treatment

Pharmacotherapy

Advanced Therapeutics

Supportive and Rehabilitative Care

Treatment Outcomes

MAXO Terms

13. Prevention

Prevention Levels

Genetic Screening and Counseling

Behavioral Interventions

14. Other Species / Natural Disease